The	DT	O
recommended	VBN	O
starting	NN	O
and	CC	O
target	NN	O
dose	NN	O
for	IN	O
ABILIFY	NNP	O
is	VBZ	O
10	CD	DOS
or	CC	O
15	CD	DOS
mg/day	NN	UNIT
administered	VBN	O
on	IN	O
a	DT	O
once-a-day	JJ	O
schedule	NN	O
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
0	0	O
		
Administer	RB	O
ABLAVAR	NNP	O
as	IN	O
an	DT	O
intravenous	JJ	O
bolus	NN	O
injection	NN	O
,	,	O
manually	RB	O
or	CC	O
by	IN	O
power	NN	O
injection	NN	O
,	,	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.12	CD	DOS
mL/kg	NNS	UNIT
body	NN	O
weight	NN	O
(	(	O
0.03	CD	DOS
mmol/kg	NN	UNIT
)	)	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
up	IN	O
to	TO	O
30	CD	O
seconds	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
25-30	JJ	DOS
mL	NN	UNIT
normal	JJ	O
saline	JJ	O
flush	NN	O
0	0	O
		
The	DT	O
suggested	JJ	O
total	JJ	O
daily	JJ	O
dose	NN	O
is	VBZ	O
8	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
in	IN	O
divided	JJ	O
doses	NNS	O
0	0	O
		
Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
ACLOVATE??	NNP	O
(	(	O
alclometasone	JJ	O
dipropionate	NN	O
)	)	O
Cream	NN	O
or	CC	O
Ointment	NN	O
to	TO	O
the	DT	O
affected	JJ	O
skin	NN	O
areas	NNS	O
2	CD	O
or	CC	O
3	CD	O
times	NNS	O
daily	RB	O
;	:	O
massage	VB	O
gently	RB	O
until	IN	O
the	DT	O
medication	NN	O
disappears	VBZ	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ACTEMRA	NNP	O
for	IN	O
adult	NN	O
patients	NNS	O
given	VBN	O
as	IN	O
a	DT	O
60-minute	JJ	O
single	JJ	DOS
intravenous	JJ	UNIT
drip	NN	UNIT
infusion	NN	UNIT
is	VBZ	O
4	CD	DOS
mg	NN	UNIT
per	IN	O
kg	NN	O
every	DT	O
4	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
an	DT	O
increase	NN	O
to	TO	O
8	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
every	DT	O
4	CD	O
weeks	NNS	O
based	VBN	O
on	IN	O
clinical	JJ	O
response	NN	O
0	0	O
		
A	DT	O
single	JJ	DOS
intravenous	JJ	UNIT
dose	NN	UNIT
of	IN	O
ACTHREL??	NNP	O
at	IN	O
1	CD	DOS
mcg/kg	NN	UNIT
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
testing	NN	O
of	IN	O
pituitary	JJ	O
corticotrophin	NN	O
function	NN	O
0	0	O
		
Adults	NNS	O
:	:	O
The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
oral	JJ	O
doxycycline	NN	O
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
(	(	O
administered	VBN	O
100	CD	DOS
mg	NN	UNIT
every	DT	O
12	CD	O
hours	NNS	O
)	)	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
100	CD	DOS
mg	JJ	UNIT
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
Actigall	NNP	O
treatment	NN	O
of	IN	O
radiolucent	JJ	O
gallbladder	NN	O
stones	NNS	O
is	VBZ	O
8	CD	DOS
-	:	O
10	CD	DOS
mg/kg/day	NN	UNIT
given	VBN	O
in	IN	O
2	CD	O
or	CC	O
3	CD	O
divided	JJ	O
doses	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
patients	NNS	O
without	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
is	VBZ	O
15	CD	DOS
mg	NN	UNIT
or	CC	O
30	CD	DOS
mg	NNS	UNIT
once	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ACULAR	NNP	O
LS	NNP	O
(	(	O
ketorolac	FW	O
tromethamine	VB	O
ophthalmic	JJ	O
solution	NN	O
)	)	O
ophthalmic	JJ	O
solution	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
four	CD	O
times	NNS	O
a	DT	O
day	NN	O
in	IN	O
the	DT	O
operated	JJ	O
eye	NN	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
and	CC	O
burning/stinging	NN	O
for	IN	O
up	IN	O
to	TO	O
4	CD	O
days	NNS	O
following	VBG	O
corneal	JJ	O
refractive	JJ	O
surgery	NN	O
0	0	O
		
Adacel	NNP	O
vaccine	NN	O
is	VBZ	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
0.5	CD	DOS
mL	NN	UNIT
intramuscular	JJ	UNIT
injection	NN	UNIT
into	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
0	0	O
		
It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
Adalat	NNP	O
CC	NNP	O
be	VB	O
administered	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ADDYI	NNP	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
administered	VBN	O
orally	RB	O
once	RB	O
per	IN	O
day	NN	O
at	IN	O
bedtime	NN	O
0	0	O
		
A	DT	O
single	JJ	DOS
vaccine	NN	UNIT
dose	NN	UNIT
is	VBZ	O
administered	VBN	O
orally	RB	O
as	IN	O
two	CD	DOS
tablets	NNS	UNIT
:	:	O
one	CD	DOS
tablet	NN	UNIT
of	IN	O
Adenovirus	NNP	O
Type	NNP	O
4	CD	O
and	CC	O
one	CD	DOS
tablet	NN	UNIT
of	IN	O
Adenovirus	NNP	O
Type	NNP	O
7	CD	O
0	0	O
		
The	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
ADLYXIN	NNP	O
is	VBZ	O
10	CD	DOS
mcg	NN	UNIT
subcutaneously	RB	O
once	RB	O
daily	JJ	O
for	IN	O
14	CD	O
days	NNS	O
0	0	O
		
For	IN	O
adults	NNS	O
(	(	O
???	JJ	O
16	CD	O
years	NNS	O
of	IN	O
age	NN	O
)	)	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
10	CD	DOS
mCi	NN	UNIT
(	(	O
370	CD	DOS
MBq	NNP	UNIT
)	)	O
0	0	O
		
ADVAIR	NNP	O
HFA	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
2	CD	DOS
inhalations	NNS	UNIT
twice	RB	O
daily	RB	O
by	IN	O
the	DT	O
orally	RB	O
inhaled	VBN	O
route	NN	O
only	RB	O
0	0	O
		
Administer	NNP	O
as	IN	O
a	DT	O
single	JJ	DOS
0.5	CD	DOS
mL	NN	UNIT
dose	NN	UNIT
0	0	O
		
The	DT	O
usual	JJ	O
IV	NNP	O
dose	NN	O
is	VBZ	O
16	CD	DOS
mg/m??	NN	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
AllerNaze	NNP	O
(	(	O
triamcinolone	JJ	O
acetonide	NN	O
nasal	IN	O
spray	NN	O
)	)	O
for	IN	O
most	JJS	O
patients	NNS	O
is	VBZ	O
200	CD	DOS
mcg	JJ	UNIT
per	IN	O
day	NN	O
given	VBN	O
as	IN	O
2	CD	DOS
sprays	NNS	UNIT
(	(	O
approximately	RB	O
50	CD	DOS
mcg/spray	NN	UNIT
)	)	O
in	IN	O
each	DT	O
nostril	NN	O
once	RB	O
a	DT	O
day	NN	O
0	0	O
		
The	DT	O
maximum	JJ	O
single	JJ	O
recommended	VBD	O
dose	NN	O
of	IN	O
ALSUMA	NNP	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
injected	VBD	O
subcutaneously	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
for	IN	O
patients	NNS	O
not	RB	O
receiving	VBG	O
a	DT	O
diuretic	JJ	O
is	VBZ	O
2.5	CD	DOS
mg	NN	UNIT
once	RB	O
a	DT	O
day	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
is	VBZ	O
20	CD	DOS
,	,	O
40	CD	DOS
,	,	O
or	CC	O
60	CD	DOS
mg	NN	UNIT
once	RB	O
a	DT	O
day	NN	O
given	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
20-60	JJ	DOS
mg/day	NN	UNIT
,	,	O
in	IN	O
single	JJ	O
doses	NNS	O
taken	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
AMARYL	NNP	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
or	CC	O
2	CD	DOS
mg	NNS	UNIT
once	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
for	IN	O
women	NNS	O
and	CC	O
either	DT	O
5	CD	DOS
or	CC	O
10	CD	DOS
mg	NN	UNIT
for	IN	O
men	NNS	O
,	,	O
taken	VBN	O
only	RB	O
once	RB	O
per	IN	O
night	NN	O
immediately	RB	O
before	IN	O
bedtime	NN	O
with	IN	O
at	IN	O
least	JJS	O
7??"8	CD	O
hours	NNS	O
remaining	VBG	O
before	IN	O
the	DT	O
planned	JJ	O
time	NN	O
of	IN	O
awakening	VBG	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
6.25	CD	DOS
mg	NN	UNIT
for	IN	O
women	NNS	O
and	CC	O
either	DT	O
6.25	CD	DOS
or	CC	O
12.5	CD	DOS
mg	NN	UNIT
for	IN	O
men	NNS	O
,	,	O
taken	VBN	O
only	RB	O
once	RB	O
per	IN	O
night	NN	O
immediately	RB	O
before	IN	O
bedtime	NN	O
with	IN	O
at	IN	O
least	JJS	O
7-8	JJ	O
hours	NNS	O
remaining	VBG	O
before	IN	O
the	DT	O
planned	JJ	O
time	NN	O
of	IN	O
awakening	VBG	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMERGE	NNP	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
or	CC	O
2.5	CD	DOS
mg	NN	UNIT
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	O
,	,	O
children	NNS	O
and	CC	O
older	JJR	O
infants	NNS	O
(	(	O
see	VB	O
WARNINGS	NNP	O
box	NN	O
)	)	O
with	IN	O
normal	JJ	O
renal	JJ	O
function	NN	O
is	VBZ	O
15	CD	DOS
mg/kg/day	NN	UNIT
divided	VBD	O
into	IN	O
2	CD	O
or	CC	O
3	CD	O
equal	JJ	O
doses	NNS	O
administered	VBN	O
at	IN	O
equally-divided	JJ	O
intervals	NNS	O
,	,	O
i.e.	NN	O
,	,	O
7.5	CD	DOS
mg/kg	NN	UNIT
q12h	NN	O
or	CC	O
5	CD	DOS
mg/kg	JJ	UNIT
q8h	NN	O
0	0	O
		
For	IN	O
peripheral	JJ	O
intravenous	JJ	O
infusion	NN	O
,	,	O
1	CD	DOS
to	TO	O
1.5	CD	DOS
g/kg/day	NN	UNIT
of	IN	O
total	JJ	O
amino	NN	O
acids	NNS	O
will	MD	O
reduce	VB	O
protein	JJ	O
catabolism	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AMJEVITA	NNP	O
for	IN	O
adult	NN	O
patients	NNS	O
with	IN	O
rheumatoid	JJ	O
arthritis	NN	O
(	(	O
RA	NNP	O
)	)	O
,	,	O
psoriatic	JJ	O
arthritis	NN	O
(	(	O
PsA	NNP	O
)	)	O
,	,	O
or	CC	O
ankylosing	VBG	O
spondylitis	NN	O
(	(	O
AS	IN	O
)	)	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
administered	VBN	O
every	DT	O
other	JJ	O
week	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
adult	NN	O
dose	NN	O
for	IN	O
most	JJS	O
patients	NNS	O
is	VBZ	O
one	CD	DOS
(	(	O
1	CD	DOS
)	)	O
AMRIX	$	O
15	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
taken	VBN	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
ANDRODERM	NNP	O
4	CD	DOS
mg/day	NN	UNIT
system	NN	UNIT
(	(	O
not	RB	O
two	CD	DOS
2	CD	DOS
mg/day	JJ	UNIT
systems	NNS	UNIT
)	)	O
applied	VBD	O
nightly	RB	O
for	IN	O
24	CD	O
hours	NNS	O
,	,	O
delivering	VBG	O
approximately	RB	O
4	CD	O
mg	NNS	O
of	IN	O
testosterone	NN	O
per	IN	O
day	NN	O
0	0	O
		
Initial	JJ	O
200-400	JJ	DOS
mg	NNS	UNIT
daily	RB	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
,	,	O
with	IN	O
meals	NNS	O
or	CC	O
milk	NN	O
,	,	O
gradually	RB	O
increasing	VBG	O
when	WRB	O
necessary	JJ	O
to	TO	O
full	JJ	O
maintenance	NN	O
dosage	NN	O
in	IN	O
one	CD	O
week	NN	O
0	0	O
		
One	CD	DOS
suppository	NN	UNIT
in	IN	O
the	DT	O
rectum	NN	O
morning	NN	O
and	CC	O
night	NN	O
for	IN	O
two	CD	O
weeks	NNS	O
,	,	O
in	IN	O
nonspecific	JJ	O
proctitis	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ARAVA	NNP	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
target	NN	O
dose	NN	O
of	IN	O
aripiprazole	NN	O
is	VBZ	O
10	CD	DOS
mg/day	NN	UNIT
0	0	O
		
The	DT	O
initial	JJ	O
intramuscular	JJ	O
dosage	NN	O
of	IN	O
triamcinolone	NN	O
diacetate	NN	O
injectable	JJ	O
suspension	NN	O
may	MD	O
vary	VB	O
from	IN	O
3	CD	DOS
to	TO	O
48	CD	DOS
mg	NNS	UNIT
per	IN	O
day	NN	O
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
0	0	O
		
The	DT	O
range	NN	O
of	IN	O
initial	JJ	O
doses	NNS	O
is	VBZ	O
0.11	CD	DOS
to	TO	O
1.6	CD	DOS
mg/kg/day	NN	UNIT
in	IN	O
three	CD	DOS
or	CC	O
four	CD	DOS
divided	VBN	UNIT
doses	NNS	UNIT
(	(	O
3.2	CD	DOS
to	TO	O
48	CD	DOS
mg/m??bsa/day	NN	UNIT
)	)	O
0	0	O
		
ARMONAIR	NNP	O
RESPICLICK	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
1	CD	DOS
inhalation	NN	UNIT
twice	RB	O
daily	RB	O
(	(	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
by	IN	O
the	DT	O
orally	RB	O
inhaled	JJ	O
route	NN	O
0	0	O
		
Most	JJS	O
patients	NNS	O
require	VBP	O
60	CD	DOS
to	TO	O
120	CD	DOS
mg/day	NN	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AROMASIN	NNP	O
in	IN	O
early	JJ	O
and	CC	O
advanced	JJ	O
breast	NN	O
cancer	NN	O
is	VBZ	O
one	CD	DOS
25	CD	DOS
mg	NN	UNIT
tablet	NN	UNIT
once	IN	O
daily	JJ	O
after	IN	O
a	DT	O
meal	NN	O
0	0	O
		
For	IN	O
adults	NNS	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Asacol	NNP	O
is	VBZ	O
two	CD	DOS
400	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
to	TO	O
be	VB	O
taken	VBN	O
three	CD	O
times	NNS	O
daily	JJ	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
(	(	O
total	JJ	O
daily	RB	O
dose	NN	O
of	IN	O
2.4	CD	DOS
grams	NNS	UNIT
)	)	O
,	,	O
for	IN	O
a	DT	O
duration	NN	O
of	IN	O
6	CD	O
weeks	NNS	O
[	JJ	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
0	0	O
		
The	DT	O
average	JJ	O
protective	JJ	O
dose	NN	O
of	IN	O
vitamin	NN	O
C	NNP	O
for	IN	O
adults	NNS	O
is	VBZ	O
70	CD	DOS
to	TO	O
150	CD	DOS
mg	NNS	UNIT
daily	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Astelin	NNP	O
Nasal	NNP	O
Spray	NNP	O
in	IN	O
adults	NNS	O
and	CC	O
adolescent	JJ	O
patients	NNS	O
12	CD	O
years	NNS	O
and	CC	O
older	JJR	O
with	IN	O
seasonal	JJ	O
allergic	JJ	O
rhinitis	NN	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
sprays	NNS	UNIT
per	IN	O
nostril	JJ	O
twice	JJ	O
daily	RB	O
0	0	O
		
ASTEPRO	RB	O
0.1	CD	O
%	NN	O
,	,	O
1	CD	DOS
spray	NN	UNIT
per	IN	O
nostril	JJ	O
twice	JJ	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
10	CD	DOS
to	TO	O
20	CD	DOS
mg/kg	NNS	UNIT
daily	RB	O
intravenously	RB	O
for	IN	O
8	CD	O
to	TO	O
14	CD	O
days	NNS	O
0	0	O
		
Atralin	NNP	O
Gel	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
once	RB	O
daily	JJ	O
,	,	O
before	IN	O
bedtime	NN	O
,	,	O
to	TO	O
the	DT	O
skin	NN	O
where	WRB	O
acne	NN	O
lesions	NNS	O
appear	VBP	O
,	,	O
using	VBG	O
a	DT	O
thin	JJ	O
layer	NN	O
to	TO	O
cover	VB	O
the	DT	O
entire	JJ	O
affected	JJ	O
area	NN	O
0	0	O
		
Adults	NNS	O
and	CC	O
pediatric	JJ	O
patients	NNS	O
12	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
older	JJR	O
with	IN	O
body	NN	O
weight	NN	O
at	IN	O
least	JJS	O
40	CD	O
kg	NN	O
(	(	O
at	IN	O
least	JJS	O
88	CD	O
lbs	NN	O
)	)	O
The	DT	O
dose	NN	O
of	IN	O
ATRIPLA	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
once	IN	O
daily	JJ	O
taken	VBN	O
orally	RB	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
AVAPRO	NNP	O
is	VBZ	O
150	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Aveed	NNP	O
is	VBZ	O
3	CD	DOS
mL	NN	UNIT
(	(	O
750	CD	DOS
mg	NN	UNIT
)	)	O
injected	VBD	O
intramuscularly	RB	O
,	,	O
followed	VBN	O
by	IN	O
3	CD	DOS
mL	NNS	UNIT
(	(	O
750	CD	DOS
mg	NN	UNIT
)	)	O
injected	VBD	O
after	IN	O
4	CD	O
weeks	NNS	O
,	,	O
then	RB	O
3	CD	DOS
mL	NNS	UNIT
(	(	O
750	CD	DOS
mg	NN	UNIT
)	)	O
injected	VBD	O
every	DT	O
10	CD	O
weeks	NNS	O
thereafter	RB	O
0	0	O
		
AVITA??	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
once	RB	O
a	DT	O
day	NN	O
,	,	O
in	IN	O
the	DT	O
evening	NN	O
,	,	O
to	TO	O
the	DT	O
skin	NN	O
where	WRB	O
acne	NN	O
lesions	NNS	O
appear	VBP	O
,	,	O
using	VBG	O
enough	JJ	O
to	TO	O
cover	VB	O
the	DT	O
entire	JJ	O
affected	JJ	O
area	NN	O
lightly	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
30	CD	DOS
micrograms	NN	UNIT
once	RB	O
a	DT	O
week	NN	O
0	0	O
		
Active	JJ	O
Duodenal	NNP	O
Ulcer	NNP	O
??"	VBZ	O
The	DT	O
recommended	JJ	O
oral	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	O
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
at	IN	O
bedtime	NN	O
0	0	O
		
When	WRB	O
AZILECT	NNP	O
is	VBZ	O
prescribed	VBN	O
as	IN	O
monotherapy	NN	O
or	CC	O
as	IN	O
adjunct	JJ	O
therapy	NN	O
in	IN	O
patients	NNS	O
not	RB	O
taking	VBG	O
levodopa	NN	O
,	,	O
patients	NNS	O
may	MD	O
start	VB	O
AZILECT	NNP	O
at	IN	O
the	DT	O
recommended	JJ	O
dose	NN	O
of	IN	O
1	CD	DOS
mg	NNS	UNIT
administered	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	JJ	O
starting	VBG	O
daily	JJ	O
dose	NN	O
of	IN	O
BANZEL	NNP	O
in	IN	O
pediatric	JJ	O
patients	NNS	O
with	IN	O
Lennox-Gastaut	NNP	O
Syndrome	NNP	O
is	VBZ	O
approximately	RB	O
10	CD	DOS
mg/kg	NNS	UNIT
administered	VBN	O
in	IN	O
two	CD	O
equally	RB	O
divided	JJ	O
doses	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BAVENCIO	NNP	O
is	VBZ	O
10	CD	DOS
mg/kg	NN	UNIT
administered	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
60	CD	O
minutes	NNS	O
every	DT	O
2	CD	O
weeks	NNS	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
0	0	O
		
The	DT	O
dosage	NN	O
range	NN	O
is	VBZ	O
0.2	CD	DOS
mg	NN	UNIT
to	TO	O
0.8	CD	DOS
mg	NNS	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BELVIQ	NNP	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
administered	VBN	O
orally	RB	O
twice	JJ	O
daily	RB	O
0	0	O
		
Pediatric	JJ	O
Patients	NNS	O
,	,	O
other	JJ	O
than	IN	O
premature	JJ	O
infants	NNS	O
and	CC	O
neonates	NNS	O
:	:	O
5	CD	DOS
mg/kg/24	NN	UNIT
hr	NN	O
or	CC	O
150	CD	DOS
mg/m??/24	JJ	UNIT
hr	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
regimen	NNS	O
is	VBZ	O
10	CD	DOS
mg/kg	NN	UNIT
at	IN	O
2-week	JJ	O
intervals	NNS	O
for	IN	O
the	DT	O
first	JJ	O
3	CD	O
doses	NNS	O
and	CC	O
at	IN	O
4-week	JJ	O
intervals	NNS	O
thereafter	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
four	CD	O
times	NNS	O
a	DT	O
day	NN	O
0	0	O
		
Adults	NNS	O
and	CC	O
Children	NNP	O
over	IN	O
10	CD	O
years	NNS	O
of	IN	O
age	NN	O
:	:	O
Usual	JJ	O
dose	NN	O
is	VBZ	O
one	CD	DOS
100	CD	DOS
mg	NN	UNIT
or	CC	O
200	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
as	IN	O
needed	VBN	O
for	IN	O
cough	NN	O
0	0	O
		
Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
,	,	O
four	CD	O
to	TO	O
twelve	VB	O
hours	NNS	O
apart	RB	O
for	IN	O
7	CD	O
days	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BEXTRA	NNP	O
Tablets	NNP	O
for	IN	O
the	DT	O
relief	NN	O
of	IN	O
the	DT	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
arthritis	NN	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BIVIGAM	NNP	O
for	IN	O
replacement	NN	O
therapy	NN	O
in	IN	O
primary	JJ	O
humoral	JJ	O
immunodeficiency	NN	O
(	(	O
PI	NNP	O
)	)	O
is	VBZ	O
300	CD	DOS
to	TO	O
800	CD	DOS
mg/kg	NNS	UNIT
body	NN	O
weight	VBD	O
administered	VBN	O
every	DT	O
3	CD	O
to	TO	O
4	CD	O
weeks	NNS	O
0	0	O
		
Hodgkin	NNP	O
's	POS	O
disease	NN	O
-	:	O
0.25	CD	DOS
to	TO	O
0.5	CD	DOS
units/kg	NN	UNIT
(	(	O
10	CD	DOS
to	TO	O
20	CD	DOS
units/m??	NN	UNIT
)	)	O
given	VBN	O
intravenously	RB	O
,	,	O
intramuscularly	RB	O
,	,	O
or	CC	O
subcutaneously	RB	O
weekly	JJ	O
or	CC	O
twice	JJ	O
weekly	RB	O
0	0	O
		
For	IN	O
conjunctivitis	NN	O
and	CC	O
other	JJ	O
superficial	JJ	O
ocular	JJ	O
infections	NNS	O
:	:	O
Instill	NNP	O
one	CD	DOS
or	CC	O
two	CD	DOS
drops	NNS	UNIT
into	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
every	DT	O
two	CD	O
to	TO	O
three	CD	O
hours	NNS	O
initially	RB	O
0	0	O
		
The	DT	O
usual	JJ	O
initial	JJ	O
dosage	NN	O
of	IN	O
BLOCADREN	NNP	O
(	(	O
timolol	NN	O
)	)	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
twice	RB	O
a	DT	O
day	NN	O
,	,	O
whether	IN	O
used	VBN	O
alone	RB	O
or	CC	O
added	VBN	O
to	TO	O
diuretic	JJ	O
therapy	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BONIVA	NNP	O
Injection	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
postmenopausal	JJ	O
osteoporosis	NN	O
is	VBZ	O
3	CD	DOS
mg	NN	UNIT
every	DT	O
3	CD	O
months	NNS	O
administered	VBN	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
15	CD	O
to	TO	O
30	CD	O
seconds	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
BRISDELLE	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
VMS	NNP	O
is	VBZ	O
7.5	CD	DOS
mg	NN	UNIT
once	RB	O
daily	JJ	O
,	,	O
at	IN	O
bedtime	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
total	JJ	O
daily	JJ	O
dosage	NN	O
of	IN	O
Bumex	NNP	O
(	(	O
bumetanide	NN	O
)	)	O
is	VBZ	O
0.5	CD	DOS
mg	NN	UNIT
to	TO	O
2	CD	DOS
mg	NNS	UNIT
and	CC	O
in	IN	O
most	JJS	O
patients	NNS	O
is	VBZ	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
0	0	O
		
Initial	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
adults	NNS	O
is	VBZ	O
100	CD	DOS
to	TO	O
200	CD	DOS
mL	NNS	UNIT
and	CC	O
for	IN	O
children	NNS	O
2.5	CD	DOS
to	TO	O
5	CD	DOS
mL	NNS	UNIT
per	IN	O
kilogram	NN	O
body	NN	O
weight	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
total	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
BUPHENYL	NNP	O
Tablets	NNP	O
and	CC	O
Powder	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
urea	JJ	O
cycle	NN	O
disorders	NNS	O
is	VBZ	O
450-600	JJ	DOS
mg/kg/day	NN	UNIT
in	IN	O
patients	NNS	O
weighing	VBG	O
less	JJR	O
than	IN	O
20	CD	O
kg	NN	O
,	,	O
or	CC	O
9.9-13.0	CD	DOS
g/m??/day	NN	UNIT
in	IN	O
larger	JJR	O
patients	NNS	O
0	0	O
		
Adults	NNS	O
:	:	O
The	DT	O
usual	JJ	O
dosage	NN	O
for	IN	O
persons	NNS	O
13	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
over	NN	O
is	VBZ	O
1	CD	DOS
ml	NN	UNIT
Buprenex	NNP	O
(	(	O
buprenorphine	NN	O
)	)	O
(	(	O
0.3	CD	DOS
mg	RB	UNIT
buprenorphine	NN	O
)	)	O
given	VBN	O
by	IN	O
deep	JJ	O
intramuscular	NN	O
or	CC	O
slow	VB	O
(	(	O
over	IN	O
at	IN	O
least	JJS	O
2	CD	O
minutes	NNS	O
)	)	O
intravenous	JJ	O
injection	NN	O
at	IN	O
up	IN	O
to	TO	O
6-hour	JJ	O
intervals	NNS	O
,	,	O
as	IN	O
needed	VBN	O
0	0	O
		
Buprenorphine	NNP	O
and	CC	O
naloxone	RB	O
sublingual	JJ	O
tablets	NNS	O
are	VBP	O
administered	VBN	O
sublingually	RB	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	O
dose	NN	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
atorvastatin	NN	O
is	VBZ	O
10	CD	DOS
or	CC	O
20	CD	DOS
mg	NNS	UNIT
once	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
CALCIJEX??	NNP	O
is	VBZ	O
0.5	CD	DOS
mcg	NN	UNIT
(	(	O
0.01	CD	DOS
mcg/kg	NN	UNIT
)	)	O
administered	VBD	O
three	CD	O
times	NNS	O
weekly	RB	O
,	,	O
every	DT	O
other	JJ	O
day	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dose	NN	O
of	IN	O
this	DT	O
preparation	NN	O
varies	VBZ	O
from	IN	O
5	CD	DOS
to	TO	O
10	CD	DOS
mL	NNS	UNIT
at	IN	O
intervals	NNS	O
of	IN	O
1	CD	O
to	TO	O
3	CD	O
days	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Calcium	NNP	O
Disodium	NNP	O
Versenate	NNP	O
for	IN	O
asymptomatic	JJ	O
adults	NNS	O
and	CC	O
pediatric	JJ	O
patients	NNS	O
whose	WP$	O
blood	JJ	O
lead	NN	O
level	NN	O
is	VBZ	O
<	JJ	O
70	CD	DOS
mcg/dl	NN	UNIT
but	CC	O
>	$	O
20	CD	DOS
mcg/dl	NN	UNIT
(	(	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
recommended	VBD	O
upper	JJ	O
allowable	JJ	O
level	NN	O
)	)	O
is	VBZ	O
1000	CD	DOS
mg/m2/day	NN	UNIT
whether	IN	O
given	VBN	O
intravenously	RB	O
or	CC	O
intramuscularly	RB	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dose	NN	O
is	VBZ	O
1	CD	DOS
or	CC	O
2	CD	DOS
tablets	NNS	UNIT
(	(	O
25	CD	DOS
or	CC	O
50	CD	DOS
mg	NN	UNIT
)	)	O
4	CD	O
times	NNS	O
a	DT	O
day	NN	O
preferably	RB	O
with	IN	O
meals	NNS	O
and	CC	O
at	IN	O
bedtime	NN	O
0	0	O
		
The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
CAPOTEN	NNP	O
(	(	O
captopril	JJ	O
tablets	NNS	O
,	,	O
USP	NNP	O
)	)	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
b.i.d	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
adult	NN	O
oral	JJ	O
dosage	NN	O
for	IN	O
duodenal	JJ	O
ulcer	NN	O
is	VBZ	O
1	CD	DOS
g	NN	UNIT
(	(	O
10	CD	DOS
mL/2	NN	UNIT
teaspoons	NNS	O
)	)	O
four	CD	O
times	NNS	O
per	IN	O
day	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dosage	NN	O
of	IN	O
CARDURA	NNP	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
given	VBN	O
once	RB	O
daily	JJ	O
either	CC	O
in	IN	O
the	DT	O
morning	NN	O
or	CC	O
evening	NN	O
0	0	O
		
0.1	CD	DOS
mg	JJ	UNIT
tablet	NN	O
twice	RB	O
daily	RB	O
(	(	O
morning	NN	O
and	CC	O
bedtime	NN	O
)	)	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
daily	RB	O
dose	NN	O
of	IN	O
CEFOBID	NNP	O
(	(	O
sterile	JJ	O
cefoperazone	NN	O
)	)	O
is	VBZ	O
2	CD	DOS
to	TO	O
4	CD	DOS
grams	NNS	UNIT
per	IN	O
day	NN	O
administered	VBN	O
in	IN	O
equally	RB	O
divided	JJ	O
doses	NNS	O
every	DT	O
12	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
CELESTONE	NNP	O
Syrup	NNP	O
(	(	O
betamethasone	NN	O
)	)	O
may	MD	O
vary	VB	O
from	IN	O
0.6	CD	DOS
mg	NNS	UNIT
to	TO	O
7.2	CD	DOS
mg	NNS	UNIT
per	IN	O
day	NN	O
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
0	0	O
		
A	DT	O
small	JJ	O
amount	NN	O
of	IN	O
CENTANY??	NNP	O
ointment	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
three	CD	O
times	NNS	O
daily	RB	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
CERDELGA	NNP	O
is	VBZ	O
84	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
in	IN	O
CYP2D6	NNP	O
EMs	NNP	O
and	CC	O
IMs	NNP	O
0	0	O
		
The	DT	O
normal	JJ	O
adult	NN	O
(	(	O
70	CD	O
kg	NN	O
)	)	O
dose	NN	O
is	VBZ	O
0.259-0.925	JJ	DOS
GBq	NNP	UNIT
(	(	O
7-25	JJ	DOS
mCi	NN	UNIT
)	)	O
as	IN	O
Tc99m	NNP	O
labeled	VBD	O
leukocytes	NNS	O
by	IN	O
intravenous	JJ	O
injection	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dosage	NN	O
is	VBZ	O
1	CD	DOS
or	CC	O
2	CD	DOS
mg	NN	UNIT
2	CD	O
times	NNS	O
a	DT	O
day	NN	O
0	0	O
		
One	CD	DOS
tablet	NN	UNIT
three	CD	O
or	CC	O
four	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
CHOLBAM	NNP	O
is	VBZ	O
10	CD	DOS
to	TO	O
15	CD	DOS
mg/kg	NNS	UNIT
administered	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
,	,	O
or	CC	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
,	,	O
in	IN	O
pediatric	JJ	O
patients	NNS	O
and	CC	O
in	IN	O
adults	NNS	O
0	0	O
		
Metastatic	JJ	O
Testicular	NNP	O
Tumors	NNPS	O
-	:	O
The	DT	O
usual	JJ	O
cisplatin	NN	O
(	(	O
cisplatin	JJ	O
injection	NN	O
)	)	O
dose	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
testicular	JJ	O
cancer	NN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
approved	VBN	O
chemotherapeutic	JJ	O
agents	NNS	O
is	VBZ	O
20	CD	DOS
mg/m2	JJ	UNIT
IV	NNP	O
daily	NN	O
for	IN	O
5	CD	O
days	NNS	O
per	IN	O
cycle	NN	O
0	0	O
		
The	DT	O
maximum	JJ	O
daily	JJ	O
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
12	CD	DOS
grams	NNS	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
CLARINEX-D	NNP	O
24	CD	O
HOUR	NNP	O
Extended	NNP	O
Release	NNP	O
Tablets	NNP	O
is	VBZ	O
1	CD	DOS
tablet	NN	UNIT
once	RB	O
daily	JJ	O
,	,	O
administered	VBN	O
with	IN	O
or	CC	O
without	IN	O
a	DT	O
meal	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
1.34	CD	DOS
mg	NN	UNIT
(	(	O
1/2	CD	DOS
tablet	NN	UNIT
)	)	O
twice	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
CLEOCIN	NNP	O
Vaginal	NNP	O
Ovule	NNP	UNIT
(	(	O
containing	VBG	O
clindamycin	NN	O
phosphate	NN	O
equivalent	NN	O
to	TO	O
100	CD	O
mg	NNS	O
clindamycin	VBP	O
per	IN	O
2.5	CD	O
g	JJ	O
suppository	NN	O
)	)	O
intravaginally	RB	O
per	IN	O
day	NN	O
,	,	O
preferably	RB	O
at	IN	O
bedtime	NN	O
,	,	O
for	IN	O
3	CD	O
consecutive	JJ	O
days	NNS	O
0	0	O
		
Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Clindamycin	NNP	O
Phosphate	NNP	O
Topical	NNP	O
Solution	NNP	O
twice	RB	O
daily	RB	O
to	TO	O
affected	JJ	O
area	NN	O
0	0	O
		
CLINDETS??	NNP	O
(	(	O
clindamycin	JJ	O
phosphate	NN	O
pledget	NN	O
)	)	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
areas	NNS	O
affected	VBN	O
by	IN	O
acne	JJ	O
twice	JJ	O
daily	RB	O
,	,	O
in	IN	O
the	DT	O
morning	NN	O
and	CC	O
at	IN	O
night	NN	O
0	0	O
		
Apply	NNP	O
Cloderm	NNP	O
(	(	O
clocortolone	NN	O
pivalate	NN	O
)	)	O
Cream	NNP	O
0.1	CD	O
%	NN	O
sparingly	RB	O
to	TO	O
the	DT	O
affected	JJ	O
areas	NNS	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
and	CC	O
rub	NN	O
in	IN	O
gently	RB	O
0	0	O
		
Adults	NNS	O
:	:	O
15	CD	DOS
to	TO	O
60	CD	DOS
mg	NN	UNIT
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
(	(	O
usual	JJ	O
adult	NN	O
dose	NN	O
,	,	O
30	CD	DOS
mg	NN	UNIT
)	)	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dosage	NN	O
for	IN	O
tablets	NNS	O
is	VBZ	O
15	CD	DOS
mg	NN	UNIT
to	TO	O
60	CD	DOS
mg	NNS	UNIT
repeated	VBD	O
up	RB	O
to	TO	O
every	DT	O
four	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
0	0	O
		
Apply	RB	O
1	CD	DOS
??"	JJ	DOS
4	CD	DOS
pumps	NNS	UNIT
up	RB	O
to	TO	O
four	CD	O
times	NNS	O
per	IN	O
day	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
COLCRYS	NNP	O
for	IN	O
prophylaxis	NN	O
of	IN	O
gout	NN	O
flares	NNS	O
for	IN	O
adults	NNS	O
and	CC	O
adolescents	NNS	O
older	JJR	O
than	IN	O
16	CD	O
years	NNS	O
of	IN	O
age	NN	O
is	VBZ	O
0.6	CD	DOS
mg	NN	UNIT
once	RB	O
or	CC	O
twice	RB	O
daily	RB	O
0	0	O
		
For	IN	O
adults	NNS	O
,	,	O
COLESTID	NNP	O
Tablets	NNP	O
are	VBP	O
recommended	VBN	O
in	IN	O
doses	NNS	O
of	IN	O
2	CD	DOS
to	TO	O
16	CD	DOS
grams/day	NN	UNIT
given	VBN	O
once	RB	O
or	CC	O
in	IN	O
divided	JJ	O
doses	NNS	O
0	0	O
		
The	DT	O
dose	NN	O
of	IN	O
COMBIVENT??	NNP	O
Inhalation	NNP	O
Aerosol	NNP	O
is	VBZ	O
two	CD	DOS
inhalations	NNS	UNIT
four	CD	O
times	NNS	O
a	DT	O
day	NN	O
0	0	O
		
Apply	NNP	O
twice	RB	O
daily	RB	O
for	IN	O
3	CD	O
consecutive	JJ	O
days	NNS	O
,	,	O
then	RB	O
discontinue	NN	O
for	IN	O
4	CD	O
consecutive	JJ	O
days	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Corlanor	NNP	O
is	VBZ	O
5	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
with	IN	O
meals	NNS	O
0	0	O
		
A	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
Cormax	NNP	O
Ointment	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
with	IN	O
gentle	JJ	O
rubbing	VBG	O
to	TO	O
the	DT	O
affected	JJ	O
skin	JJ	O
area	NN	O
twice	RB	O
daily	RB	O
,	,	O
once	RB	O
in	IN	O
the	DT	O
morning	NN	O
and	CC	O
once	RB	O
at	IN	O
night	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
clinically	RB	O
important	JJ	O
hypotension	NN	O
in	IN	O
the	DT	O
setting	NN	O
of	IN	O
anesthesia	NN	O
is	VBZ	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
5	CD	DOS
to	TO	O
10	CD	DOS
mg	NNS	UNIT
administered	VBN	O
by	IN	O
intravenous	JJ	O
bolus	NN	O
0	0	O
		
The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
CORTEF	NNP	O
Tablets	NNP	O
may	MD	O
vary	VB	O
from	IN	O
20	CD	DOS
mg	NNS	UNIT
to	TO	O
240	CD	DOS
mg	NN	UNIT
of	IN	O
hydrocortisone	NN	O
per	IN	O
day	NN	O
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
0	0	O
		
A	DT	O
small	JJ	O
quantity	NN	O
of	IN	O
the	DT	O
cream	NN	O
should	MD	O
be	VB	O
applied	VBN	O
2	CD	O
to	TO	O
4	CD	O
times	NNS	O
daily	RB	O
,	,	O
as	IN	O
required	VBN	O
0	0	O
		
A	DT	O
thin	JJ	O
film	NN	O
is	VBZ	O
applied	VBN	O
2	CD	O
to	TO	O
4	CD	O
times	NNS	O
daily	RB	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
0	0	O
		
The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
cortisone	NN	O
acetate	NN	O
may	MD	O
vary	VB	O
from	IN	O
25	CD	DOS
to	TO	O
300	CD	DOS
mg	NNS	UNIT
per	IN	O
day	NN	O
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
by	IN	O
subcutaneous	JJ	O
injection	NN	O
at	IN	O
Weeks	NNP	O
0	CD	O
,	,	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
and	CC	O
4	CD	O
followed	VBN	O
by	IN	O
300	CD	DOS
mg	NNS	UNIT
every	DT	O
4	CD	O
weeks	NNS	O
0	0	O
		
COVERA-HS	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
once	RB	O
daily	JJ	O
at	IN	O
bedtime	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
COZAAR	NNP	O
is	VBZ	O
50	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
Administer	NNP	O
CYMBALTA	NNP	O
at	IN	O
a	DT	O
total	JJ	O
dose	NN	O
of	IN	O
40	CD	DOS
mg/day	NN	UNIT
(	(	O
given	VBN	O
as	IN	O
20	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
)	)	O
to	TO	O
60	CD	DOS
mg/day	NN	UNIT
(	(	O
given	VBN	O
either	DT	O
once	RB	O
daily	JJ	O
or	CC	O
as	IN	O
30	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
)	)	O
0	0	O
		
The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
(	(	O
1/2	CD	DOS
tablet	NN	UNIT
)	)	O
two	CD	O
or	CC	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
,	,	O
adjusted	VBN	O
as	IN	O
necessary	JJ	O
to	TO	O
the	DT	O
size	NN	O
and	CC	O
response	NN	O
of	IN	O
the	DT	O
patient	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
CYSTAGON??	NNP	O
(	(	O
cysteamine	JJ	O
bitartrate	NN	O
)	)	O
maintenance	NN	O
dose	NN	O
for	IN	O
children	NNS	O
up	RB	O
to	TO	O
age	NN	O
12	CD	O
years	NNS	O
is	VBZ	O
1.3	CD	DOS
grams/m2/day	NN	UNIT
of	IN	O
the	DT	O
free	JJ	O
base	NN	O
,	,	O
given	VBN	O
in	IN	O
four	CD	O
divided	JJ	O
doses	NNS	O
0	0	O
		
Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
CYSTARAN	NNP	O
in	IN	O
each	DT	O
eye	NN	O
,	,	O
every	DT	O
waking	VBG	O
hour	NN	O
0	0	O
		
Recommended	VBN	O
starting	JJ	O
dosage	NN	O
is	VBZ	O
5	CD	DOS
mcg	JJ	UNIT
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
adult	NN	O
oral	JJ	O
dose	NN	O
of	IN	O
Cytotec	NNP	O
for	IN	O
reducing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
NSAID-induced	NNP	O
gastric	JJ	O
ulcers	NNS	O
is	VBZ	O
200	CD	DOS
mcg	NN	UNIT
four	CD	O
times	NNS	O
daily	RB	O
with	IN	O
food	NN	O
0	0	O
		
It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
the	DT	O
patient	NN	O
be	VB	O
started	VBN	O
on	IN	O
200	CD	DOS
mg	NNS	UNIT
,	,	O
two	CD	O
or	CC	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
0	0	O
		
The	DT	O
adult	NN	O
starting	VBG	O
dose	NN	O
is	VBZ	O
50	CD	DOS
to	TO	O
75	CD	DOS
mg	NN	UNIT
of	IN	O
the	DT	O
drug	NN	O
daily	RB	O
,	,	O
together	RB	O
with	IN	O
1	CD	DOS
to	TO	O
4	CD	DOS
g	JJ	UNIT
daily	RB	O
of	IN	O
a	DT	O
sulfonamide	NN	O
of	IN	O
the	DT	O
sulfapyrimidine	NN	O
type	NN	O
,	,	O
e.g	NN	O
0	0	O
		
sufadoxine	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	O
65	CD	DOS
mg	NN	UNIT
propoxyphene	NN	O
hydrochloride	NN	O
capsule	NN	O
every	DT	O
4	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
bolus	NN	O
dose	NN	O
for	IN	O
activated	JJ	O
DEFINITY	NNP	O
is	VBZ	O
10	CD	DOS
microliters	NNS	UNIT
(	(	O
microL	NN	O
)	)	O
/kg	NN	O
of	IN	O
the	DT	O
activated	JJ	O
product	NN	O
by	IN	O
intravenous	JJ	O
bolus	NN	O
injection	NN	O
within	IN	O
30-60	JJ	O
seconds	NNS	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
10	CD	DOS
mL	NN	UNIT
saline	NN	O
flush	NN	O
0	0	O
		
The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
DELTASONE	NNP	O
Tablets	NNP	O
may	MD	O
vary	VB	O
from	IN	O
5	CD	DOS
mg	NNS	UNIT
to	TO	O
60	CD	DOS
mg	NN	UNIT
of	IN	O
prednisone	NN	O
per	IN	O
day	NN	O
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
25	CD	DOS
mg/kg/day	NN	UNIT
given	VBN	O
once	RB	O
daily	JJ	O
0	0	O
		
Doses	NNS	O
of	IN	O
400	CD	DOS
mg	NNS	UNIT
to	TO	O
1000	CD	DOS
mg	NN	UNIT
of	IN	O
DEPO-PROVERA	NNP	O
Sterile	NNP	O
Aqueous	NNP	O
Suspension	NNP	O
per	IN	O
week	NN	O
are	VBP	O
recommended	VBN	O
initially	RB	O
0	0	O
		
Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Desoximetasone	NNP	O
Ointment	NNP	O
to	TO	O
the	DT	O
affected	JJ	O
skin	NN	O
areas	NNS	O
twice	RB	O
daily	RB	O
0	0	O
		
The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
Dia??eta	NNP	O
as	IN	O
initial	JJ	O
therapy	NN	O
is	VBZ	O
2.5	CD	DOS
to	TO	O
5	CD	DOS
mg	NNS	UNIT
daily	RB	O
,	,	O
administered	VBN	O
with	IN	O
breakfast	NN	O
or	CC	O
the	DT	O
first	JJ	O
main	JJ	O
meal	NN	O
0	0	O
		
The	DT	O
total	JJ	O
daily	JJ	O
dosage	NN	O
is	VBZ	O
generally	RB	O
taken	VBN	O
at	IN	O
a	DT	O
single	JJ	O
time	NN	O
each	DT	O
morning	NN	O
with	IN	O
breakfast	NN	O
0	0	O
		
The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
four	CD	DOS
tablets	NNS	UNIT
(	(	O
one	CD	O
in	IN	O
the	DT	O
morning	NN	O
,	,	O
one	CD	O
in	IN	O
the	DT	O
mid-afternoon	NN	O
and	CC	O
two	CD	O
at	IN	O
bedtime	NN	O
)	)	O
daily	RB	O
0	0	O
		
DIFFERIN??	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
affected	JJ	O
areas	NNS	O
of	IN	O
the	DT	O
skin	NN	O
,	,	O
once	RB	O
daily	JJ	O
at	IN	O
nighttime	NN	O
0	0	O
		
A	DT	O
thin	JJ	O
film	NN	O
of	IN	O
the	DT	O
gel	NN	O
should	MD	O
be	VB	O
applied	VBN	O
,	,	O
avoiding	VBG	O
eyes	NNS	O
,	,	O
lips	NNS	O
,	,	O
and	CC	O
mucous	JJ	O
membranes	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
studied	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
was	VBD	O
180	CD	DOS
mg	NN	UNIT
to	TO	O
480	CD	DOS
mg	NNS	UNIT
once	RB	O
daily	RB	O
0	0	O
		
A	DT	O
recommended	JJ	O
daily	JJ	O
maintenance	NN	O
dosage	NN	O
is	VBZ	O
usually	RB	O
4	CD	DOS
to	TO	O
8	CD	DOS
mg/kg	NNS	UNIT
0	0	O
		
The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
Diovan	NNP	O
HCT	NNP	O
160/12.5	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
The	DT	O
usual	JJ	O
dosage	NN	O
in	IN	O
adults	NNS	O
for	IN	O
maintenance	NN	O
of	IN	O
remission	NN	O
is	VBZ	O
1	CD	O
g/day	NN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
0	0	O
		
Donnatal??	NNP	O
Tablets	NNP	O
-	:	O
Adults	NNS	O
:	:	O
One	CD	DOS
or	CC	O
two	CD	DOS
Donnatal??	NNP	O
Tablets	NNPS	UNIT
three	CD	O
or	CC	O
four	CD	O
times	NNS	O
a	DT	O
day	NN	O
according	VBG	O
to	TO	O
condition	NN	O
and	CC	O
severity	NN	O
of	IN	O
symptoms	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
DORIBAX??	NNP	O
is	VBZ	O
500	CD	O
mg	NN	O
administered	VBN	O
every	DT	O
8	CD	O
hours	NNS	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
one	CD	O
hour	NN	O
in	IN	O
patients	NNS	O
???	JJ	O
18	CD	O
years	NNS	O
of	IN	O
age	NN	O
0	0	O
		
Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
Dovonex??	NNP	O
(	(	O
calcipotriene	JJ	O
ointment	NN	O
)	)	O
ointment	NN	O
once	RB	O
or	CC	O
twice	JJ	O
daily	JJ	O
and	CC	O
rub	NN	O
in	IN	O
gently	RB	O
and	CC	O
completely	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
doxorubicin	NN	O
HCl	NNP	O
is	VBZ	O
60	CD	DOS
mg/m	NN	UNIT
administered	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
bolus	NN	O
on	IN	O
day	NN	O
1	CD	O
of	IN	O
each	DT	O
21-day	JJ	O
treatment	NN	O
cycle	NN	O
,	,	O
in	IN	O
combination	NN	O
with	IN	O
cyclophosphamide	NN	O
,	,	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
four	CD	O
cycles	NNS	O
0	0	O
		
Generally	RB	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
Dritho-Scalp	NNP	O
be	VB	O
applied	VBN	O
once	RB	O
a	DT	O
day	NN	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
DUEXIS	NNP	O
(	(	O
ibuprofen	NN	O
and	CC	O
famotidine	NN	O
)	)	O
800	CD	O
mg/26.6	NN	O
mg	NN	O
is	VBZ	O
a	DT	O
single	JJ	DOS
tablet	NN	UNIT
administered	VBN	O
orally	RB	O
three	CD	O
times	NNS	O
per	IN	O
day	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
DuoNeb	NNP	O
(	(	O
ipratropium	JJ	O
bromide	NN	O
and	CC	O
albuterol	VB	O
sulfate	NN	O
)	)	O
is	VBZ	O
one	CD	O
3	CD	DOS
mL	NN	O
vial	NN	UNIT
administered	VBD	O
4	CD	O
times	NNS	O
per	IN	O
day	NN	O
via	IN	O
nebulization	NN	O
with	IN	O
up	IN	O
to	TO	O
2	CD	O
additional	JJ	O
3	CD	O
mL	NN	O
doses	NNS	O
allowed	VBN	O
per	IN	O
day	NN	O
,	,	O
if	IN	O
needed	VBN	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Duraclon	NNP	O
for	IN	O
continuous	JJ	O
epidural	JJ	O
infusion	NN	O
is	VBZ	O
30	CD	DOS
mcg/hr	NN	UNIT
0	0	O
		
Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
into	IN	O
the	DT	O
conjunctival	JJ	O
sac	NN	O
of	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
4	CD	O
times	NNS	O
daily	RB	O
for	IN	O
14	CD	O
days	NNS	O
followed	VBN	O
by	IN	O
tapering	VBG	O
as	IN	O
clinically	RB	O
indicated	VBN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
DURLAZA	NNP	O
is	VBZ	O
one	CD	DOS
capsule	NN	UNIT
(	(	O
162.5	CD	DOS
mg	NN	UNIT
)	)	O
once	RB	O
daily	JJ	O
0	0	O
		
DUTREBIS	NNP	O
is	VBZ	O
a	DT	O
fixed-dose	JJ	O
combination	NN	O
product	NN	O
containing	VBG	O
150	CD	DOS
mg	NN	UNIT
of	IN	O
lamivudine	NN	O
and	CC	O
300	CD	DOS
mg	NN	UNIT
of	IN	O
raltegravir	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
reconstituted	JJ	O
E-Z-HD	NNP	O
for	IN	O
adults	NNS	O
and	CC	O
pediatric	JJ	O
patients	NNS	O
12	CD	O
years	NNS	O
and	CC	O
older	JJR	O
is	VBZ	O
between	IN	DOS
65	CD	DOS
and	CC	DOS
135	CD	DOS
mL	NN	UNIT
given	VBN	O
orally	RB	O
(	(	O
155	CD	DOS
to	TO	O
321	CD	DOS
grams	NNS	UNIT
of	IN	O
barium	NN	O
sulfate	NN	O
,	,	O
respectively	RB	O
)	)	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosages	NNS	O
of	IN	O
ELLENCE	NNP	O
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ELLENCE	NNP	O
is	VBZ	O
100	CD	DOS
to	TO	O
120	CD	DOS
mg/m??	NNS	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ELMIRON??	NNP	O
is	VBZ	O
300	CD	DOS
mg/day	NN	UNIT
taken	VBN	O
as	IN	O
one	CD	O
100	CD	DOS
mg	NN	O
capsule	NN	UNIT
orally	RB	O
three	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
in	IN	O
the	DT	O
effected	VBN	O
eye	NN	O
up	RB	O
to	TO	O
four	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
The	DT	O
dose	NN	O
of	IN	O
Endometrin	NNP	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
administered	VBN	O
vaginally	RB	O
two	CD	O
or	CC	O
three	CD	O
times	NNS	O
daily	RB	O
starting	VBG	O
the	DT	O
day	NN	O
after	IN	O
oocyte	JJ	O
retrieval	NN	O
and	CC	O
continuing	VBG	O
for	IN	O
up	IN	O
to	TO	O
10	CD	O
weeks	NNS	O
total	JJ	O
duration	NN	O
0	0	O
		
The	DT	O
dosage	NN	O
delivered	VBN	O
is	VBZ	O
0.5-1.0	JJ	DOS
mg/kg	NN	UNIT
of	IN	O
edrophonium	NN	O
chloride	NN	O
and	CC	O
0.007-0.014	JJ	DOS
mg/kg	NN	UNIT
of	IN	O
atropine	JJ	O
sulfate	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ENTOCORT	NNP	O
EC	NNP	O
is	VBZ	O
:	:	O
9	CD	DOS
mg	NNS	UNIT
orally	RB	O
once	RB	O
daily	JJ	O
for	IN	O
up	IN	O
to	TO	O
8	CD	O
weeks	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
parenteral	NN	O
dose	NN	O
is	VBZ	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
given	VBN	O
subcutaneously	RB	O
or	CC	O
intramuscularly	RB	O
0	0	O
		
Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
EPIDUO	NNP	O
gel	NN	O
to	TO	O
affected	JJ	O
areas	NNS	O
of	IN	O
the	DT	O
face	NN	O
and/or	VBP	O
trunk	NN	O
once	RB	O
daily	RB	O
after	IN	O
washing	VBG	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
EPIVIR	NNP	O
in	IN	O
HIV-1-infected	NNP	O
adults	NNS	O
is	VBZ	O
300	CD	DOS
mg	JJ	UNIT
daily	RB	O
,	,	O
administered	VBN	O
as	IN	O
either	DT	O
150	CD	DOS
mg	NN	UNIT
taken	VBN	O
orally	RB	O
twice	JJ	O
daily	RB	O
or	CC	O
300	CD	DOS
mg	NNS	UNIT
taken	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
0	0	O
		
One	CD	DOS
tablet	NN	UNIT
is	VBZ	O
taken	VBN	O
every	DT	O
day	NN	O
,	,	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
0	0	O
		
In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
interdigital	JJ	O
tinea	NN	O
pedis	NN	O
,	,	O
ERTACZO	NNP	O
cream	NN	O
,	,	O
2	CD	O
%	NN	O
,	,	O
should	MD	O
be	VB	O
applied	VBN	O
twice	JJ	O
daily	RB	O
for	IN	O
4	CD	O
weeks	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
dosage	NN	O
is	VBZ	O
250	CD	DOS
mg	NN	UNIT
every	DT	O
6	CD	O
hours	NNS	O
;	:	O
or	CC	O
500	CD	DOS
mg	NN	UNIT
every	DT	O
12	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
dosage	NN	O
is	VBZ	O
30	CD	DOS
to	TO	O
50	CD	DOS
mg/kg/day	NN	UNIT
,	,	O
in	IN	O
equally	RB	O
divided	JJ	O
doses	NNS	O
0	0	O
		
For	IN	O
treatment	NN	O
of	IN	O
moderate	JJ	O
to	TO	O
severe	VB	O
vasomotor	NN	O
symptoms	NNS	O
or	CC	O
moderate	VB	O
to	TO	O
severe	VB	O
symptoms	NNS	O
of	IN	O
vulvar	NN	O
and	CC	O
vaginal	JJ	O
atrophy	NN	O
associated	VBN	O
with	IN	O
the	DT	O
menopause	NN	O
,	,	O
initiate	JJ	O
therapy	NN	O
with	IN	O
Estraderm	NNP	O
(	(	O
estradiol	FW	O
transdermal	NN	O
)	)	O
0.05	CD	O
applied	VBN	O
to	TO	O
the	DT	O
skin	NN	O
twice	RB	O
weekly	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
2	CD	DOS
to	TO	O
4	CD	DOS
g	NNS	UNIT
intravaginally	RB	O
per	IN	O
day	NN	O
,	,	O
adjusted	VBN	O
to	TO	O
the	DT	O
lowest	JJS	O
amount	NN	O
that	WDT	O
controls	VBZ	O
symptoms	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
intravenous	JJ	O
dose	NN	O
is	VBZ	O
1.5	CD	DOS
to	TO	O
5	CD	DOS
mL	NNS	UNIT
per	IN	O
varix	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
ETHYOL	NNP	O
(	(	O
amifostine	NN	O
)	)	O
is	VBZ	O
910	CD	DOS
mg/m2	NN	UNIT
administered	VBN	O
once	RB	O
daily	JJ	O
as	IN	O
a	DT	O
15-minute	JJ	O
i.v	NN	O
0	0	O
		
Dose	NNP	O
once-daily	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
EXONDYS	NNP	O
51	CD	O
is	VBZ	O
30	CD	DOS
milligrams	NNS	UNIT
per	IN	O
kilogram	NN	O
administered	VBN	O
once	RB	O
weekly	JJ	O
as	IN	O
a	DT	O
35	CD	O
to	TO	O
60	CD	O
minute	NN	O
intravenous	JJ	O
infusion	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
0.0625	CD	DOS
mg	NN	UNIT
(	(	O
0.25	CD	DOS
mL	NN	UNIT
)	)	O
subcutaneously	RB	O
every	DT	O
other	JJ	O
day	NN	O
,	,	O
with	IN	O
dose	JJ	O
increases	NNS	O
over	IN	O
a	DT	O
six-week	JJ	O
period	NN	O
to	TO	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
0.25	CD	DOS
mg	NN	UNIT
(	(	O
1	CD	DOS
mL	NN	UNIT
)	)	O
every	DT	O
other	JJ	O
day	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
FAMVIR	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
recurrent	NN	O
herpes	NNS	O
labialis	NN	O
is	VBZ	O
1500	CD	DOS
mg	NN	UNIT
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
0	0	O
		
The	DT	O
dosage	NN	O
of	IN	O
FARESTON	NNP	O
is	VBZ	O
60	CD	DOS
mg	NN	UNIT
,	,	O
once	RB	O
daily	JJ	O
,	,	O
orally	RB	O
0	0	O
		
Exogenous	JJ	O
Obesity	NN	O
:	:	O
One	CD	DOS
capsule	NN	UNIT
at	IN	O
approximately	RB	O
2	CD	O
hours	NNS	O
after	IN	O
breakfast	NN	O
for	IN	O
appetite	JJ	O
control	NN	O
0	0	O
		
The	DT	O
initial	JJ	O
dose	NN	O
is	VBZ	O
50	CD	DOS
to	TO	O
150	CD	DOS
mg	NNS	UNIT
per	IN	O
day	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Feraheme	NNP	O
is	VBZ	O
an	DT	O
initial	JJ	O
510	CD	DOS
mg	NN	UNIT
dose	NN	O
followed	VBN	O
by	IN	O
a	DT	O
second	JJ	O
510	CD	DOS
mg	NN	UNIT
dose	VBD	O
3	CD	O
to	TO	O
8	CD	O
days	NNS	O
later	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
range	NN	O
for	IN	O
FETZIMA	NNP	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
to	TO	O
120	CD	DOS
mg	NNS	UNIT
once	RB	O
daily	RB	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
0	0	O
		
The	DT	O
initial	JJ	O
dose	NN	O
is	VBZ	O
35	CD	DOS
to	TO	O
105	CD	DOS
mg	NNS	UNIT
per	IN	O
day	NN	O
0	0	O
		
Apply	NNP	O
and	CC	O
gently	RB	O
massage	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
FINACEA	NNP	O
Gel	NNP	O
into	IN	O
the	DT	O
affected	JJ	O
areas	NNS	O
on	IN	O
the	DT	O
face	NN	O
twice	RB	O
daily	RB	O
(	(	O
morning	NN	O
and	CC	O
evening	NN	O
)	)	O
0	0	O
		
One	CD	DOS
or	CC	O
two	CD	DOS
capsules	NNS	UNIT
every	DT	O
four	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
FLECTOR	NNP	O
PATCH	NNP	O
is	VBZ	O
one	CD	DOS
(	(	O
1	CD	DOS
)	)	O
patch	NN	UNIT
to	TO	O
the	DT	O
most	RBS	O
painful	JJ	O
area	NN	O
twice	RB	O
a	DT	O
day	NN	O
0	0	O
		
For	IN	O
most	JJS	O
patients	NNS	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
FLEXERIL	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
0	0	O
		
FLOMAX	NNP	O
capsules	VBZ	O
0.4	CD	DOS
mg	NN	UNIT
once	RB	O
daily	JJ	O
is	VBZ	O
recommended	VBN	O
as	IN	O
the	DT	O
dose	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
the	DT	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
BPH	NNP	O
0	0	O
		
Administer	RB	O
Flublok	NNP	O
as	IN	O
a	DT	O
single	JJ	DOS
0.5-mL	NN	DOS
dose	NN	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
adult	NN	O
dose	NN	O
of	IN	O
Fludarabine	NNP	O
Phosphate	NNP	O
Injection	NNP	O
is	VBZ	O
25	CD	DOS
mg/m??	NN	UNIT
diluted	VBN	O
in	IN	O
100	CD	O
to	TO	O
125	CD	O
cc	NN	O
of	IN	O
5	CD	O
%	NN	O
dextrose	JJ	O
injection	NN	O
USP	NNP	O
or	CC	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
USP	NNP	O
administered	VBD	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
approximately	RB	O
30	CD	O
minutes	NNS	O
daily	RB	O
for	IN	O
five	CD	O
consecutive	JJ	O
days	NNS	O
0	0	O
		
For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
eczematous	JJ	O
external	JJ	O
otitis	NN	O
,	,	O
using	VBG	O
the	DT	O
supplied	JJ	O
ear-dropper	NN	O
,	,	O
apply	VB	O
5	CD	DOS
drops	NNS	UNIT
of	IN	O
DermOtic??	NNP	O
Oil	NNP	O
(	(	O
fluocinolone	NN	O
acetonide	RB	O
oil	NN	O
ear	JJ	O
drops	NN	O
)	)	O
into	IN	O
the	DT	O
affected	JJ	O
ear	NN	O
0	0	O
		
Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
into	IN	O
the	DT	O
conjunctival	JJ	O
sac	NN	O
two	CD	O
to	TO	O
four	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Focalin	NNP	O
XR	NNP	O
for	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
not	RB	O
currently	RB	O
taking	VBG	O
dexmethylphenidate	NN	O
or	CC	O
racemic	JJ	O
methylphenidate	NN	O
,	,	O
or	CC	O
for	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
on	IN	O
stimulants	NNS	O
other	JJ	O
than	IN	O
methylphenidate	NN	O
,	,	O
is	VBZ	O
5	CD	DOS
mg/day	NN	UNIT
for	IN	O
pediatric	JJ	O
patients	NNS	O
and	CC	O
10	CD	DOS
mg/day	NN	UNIT
for	IN	O
adult	NN	O
patients	NNS	O
0	0	O
		
Usual	JJ	O
adult	NN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
to	TO	O
two	CD	DOS
tablets	NNS	UNIT
daily	RB	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dosage	NN	O
is	VBZ	O
1	CD	DOS
gram	NN	UNIT
administered	VBN	O
intravenously	RB	O
or	CC	O
intramuscularly	RB	O
every	DT	O
8	CD	O
to	TO	O
12	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Fortical	NNP	O
nasal	NN	O
spray	NN	O
is	VBZ	O
1	CD	DOS
spray	NN	UNIT
(	(	O
200	CD	DOS
International	NNP	UNIT
Units	NNP	UNIT
)	)	O
per	IN	O
day	NN	O
intranasally	RB	O
,	,	O
alternating	VBG	O
nostrils	JJ	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
initial	JJ	O
total	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
FOSRENOL	NNP	O
is	VBZ	O
1500	CD	DOS
mg	NN	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
FUZEON	NNP	O
is	VBZ	O
90	CD	DOS
mg	NN	UNIT
(	(	O
1	CD	DOS
mL	NN	UNIT
)	)	O
twice	RB	O
daily	RB	O
injected	VBN	O
subcutaneously	RB	O
into	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
,	,	O
anterior	JJ	O
thigh	NN	O
or	CC	O
abdomen	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Gadavist	NNP	O
for	IN	O
adult	NN	O
and	CC	O
pediatric	JJ	O
patients	NNS	O
(	(	O
including	VBG	O
term	NN	O
neonates	NNS	O
)	)	O
is	VBZ	O
0.1	CD	DOS
mL/kg	NN	UNIT
body	NN	O
weight	VBD	O
(	(	O
0.1	CD	DOS
mmol/kg	NN	UNIT
)	)	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Gammaplex	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
PI	NNP	O
is	VBZ	O
300	CD	DOS
to	TO	O
800	CD	DOS
mg/kg	NN	UNIT
(	(	O
6	CD	DOS
to	TO	O
16	CD	DOS
mL/kg	NN	UNIT
)	)	O
,	,	O
administered	VBN	O
every	DT	O
3	CD	O
to	TO	O
4	CD	O
weeks	NNS	O
0	0	O
		
The	DT	O
dose	NN	O
of	IN	O
GAMUNEX-C	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
PI	NNP	O
is	VBZ	O
300	CD	DOS
mg/kg	NN	UNIT
to	TO	O
600	CD	DOS
mg/kg	NNS	UNIT
body	NN	O
weight	NN	O
(	(	O
3	CD	DOS
mL/kg	NN	UNIT
to	TO	O
6	CD	DOS
mL/kg	NN	UNIT
)	)	O
administered	VBD	O
every	DT	O
3	CD	O
to	TO	O
4	CD	O
weeks	NNS	O
0	0	O
		
Severe	JJ	O
Infections	NNS	O
:	:	O
4	CD	DOS
tablets	NNS	UNIT
(	(	O
2	CD	DOS
g	NN	UNIT
)	)	O
initially	RB	O
,	,	O
followed	VBN	O
by	IN	O
2	CD	DOS
tablets	NNS	UNIT
(	(	O
1	CD	DOS
g	NN	UNIT
)	)	O
three	CD	O
times	NNS	O
daily	JJ	O
thereafter	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
GENVOYA	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
with	IN	O
food	NN	O
in	IN	O
adults	NNS	O
and	CC	O
pediatric	JJ	O
patients	NNS	O
12	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
older	JJR	O
with	IN	O
body	NN	O
weight	NN	O
at	IN	O
least	JJS	O
35	CD	O
kg	NN	O
and	CC	O
creatinine	JJ	O
clearance	NN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
30	CD	O
mL	NNS	O
per	IN	O
minute	NN	O
0	0	O
		
GEODON	NNP	O
Capsules	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
at	IN	O
an	DT	O
initial	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
20	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
with	IN	O
food	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
GILOTRIF	NNP	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
orally	RB	O
,	,	O
once	RB	O
daily	JJ	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
no	DT	O
longer	RB	O
tolerated	VBN	O
by	IN	O
the	DT	O
patient	NN	O
0	0	O
		
Titrate	NNP	O
GRALISE	NNP	O
to	TO	O
an	DT	O
1800	CD	DOS
mg	NN	UNIT
dose	NN	O
taken	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
with	IN	O
the	DT	O
evening	NN	O
meal	NN	O
0	0	O
		
Adults	NNS	O
and	CC	O
pediatric	JJ	O
patients	NNS	O
over	IN	O
12	CD	O
years	NNS	O
of	IN	O
age	NN	O
:	:	O
One	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
every	DT	O
12	CD	O
hours	NNS	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	DOS
tablets	NNS	UNIT
in	IN	O
24	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
GYNAZOLE???1??	NNP	O
Butoconazole	NNP	O
Nitrate	NNP	O
Vaginal	NNP	O
Cream	NNP	O
USP	NNP	O
,	,	O
2	CD	O
%	NN	O
is	VBZ	O
one	CD	DOS
applicatorful	NN	UNIT
of	IN	O
cream	NN	O
(	(	O
approximately	RB	O
5	CD	DOS
grams	NNS	UNIT
of	IN	O
the	DT	O
cream	NN	O
)	)	O
intravaginally	RB	O
0	0	O
		
Use	NNP	O
once	RB	O
or	CC	O
twice	VB	O
a	DT	O
day	NN	O
for	IN	O
up	IN	O
to	TO	O
7	CD	O
days	NNS	O
as	RB	O
needed	VBN	O
to	TO	O
relieve	VB	O
external	JJ	O
vulvar	NN	O
itching	NN	O
0	0	O
		
The	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
20	CD	DOS
mg/day	NN	UNIT
0	0	O
		
Apply	VB	O
the	DT	O
0.1	CD	O
%	NN	O
HALOG	NNP	O
(	(	O
Halcinonide	NNP	O
Cream	NNP	O
,	,	O
USP	NNP	O
)	)	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
two	CD	O
to	TO	O
three	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
0.1	CD	O
%	NN	O
HALOG	NNP	O
OINTMENT	NNP	O
(	(	O
Halcinonide	NNP	O
Ointment	NNP	O
,	,	O
USP	NNP	O
)	)	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
two	CD	O
to	TO	O
three	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
HARVONI	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
0	0	O
		
The	DT	O
amount	NN	O
usually	RB	O
administered	VBN	O
is	VBZ	O
500	CD	DOS
to	TO	O
1000	CD	DOS
mL	NN	UNIT
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	O
and	CC	O
children	NNS	O
12	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
older	JJR	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
(	(	O
1	CD	DOS
tablet	NN	UNIT
)	)	O
once	RB	O
daily	JJ	O
0	0	O
		
10	CD	DOS
mL	NN	UNIT
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	DOS
doses	NNS	UNIT
(	(	O
40	CD	DOS
mL	NN	UNIT
)	)	O
in	IN	O
24	CD	O
hours	NNS	O
0	0	O
		
Usual	JJ	O
Adult	NNP	O
Dose	NNP	O
:	:	O
One	CD	DOS
teaspoonful	NN	UNIT
(	(	O
5	CD	DOS
mL	NN	UNIT
)	)	O
after	IN	O
meals	NNS	O
and	CC	O
at	IN	O
bedtime	NN	O
,	,	O
not	RB	O
less	JJR	O
than	IN	O
4	CD	O
hours	NNS	O
apart	RB	O
(	(	O
not	RB	O
to	TO	O
exceed	VB	O
6	CD	DOS
teaspoonfuls	NNS	UNIT
in	IN	O
a	DT	O
24	CD	O
hour	NN	O
period	NN	O
)	)	O
0	0	O
		
Administer	NNP	O
HYQVIA	NNP	O
at	IN	O
300	CD	DOS
to	TO	O
600	CD	DOS
mg/kg	NNS	UNIT
at	IN	O
3	CD	O
to	TO	O
4	CD	O
week	NN	O
intervals	NNS	O
,	,	O
after	IN	O
initial	JJ	O
ramp-up	NN	O
0	0	O
		
Initiate	NNP	O
therapy	NN	O
with	IN	O
HYSINGLA	NNP	O
ER	NNP	O
20	CD	DOS
mg	NN	UNIT
orally	RB	O
every	DT	O
24	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
HYZAAR	NNP	O
is	VBZ	O
50/12.5	CD	O
(	(	O
losartan	JJ	O
50	CD	DOS
mg/hydrochlorothiazide	RB	UNIT
12.5	CD	DOS
mg	NN	UNIT
)	)	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
IBRANCE	NNP	O
is	VBZ	O
a	DT	O
125	CD	DOS
mg	NN	UNIT
capsule	NN	O
taken	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
for	IN	O
21	CD	O
consecutive	JJ	O
days	NNS	O
followed	VBN	O
by	IN	O
7	CD	O
days	NNS	O
off	RB	O
treatment	NN	O
to	TO	O
comprise	VB	O
a	DT	O
complete	JJ	O
cycle	NN	O
of	IN	O
28	CD	O
days	NNS	O
0	0	O
		
Start	NNP	O
dosing	VBG	O
with	IN	O
45	CD	DOS
mg	NNS	UNIT
once	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
25	CD	DOS
to	TO	O
40	CD	DOS
IU	NNP	UNIT
of	IN	O
IDELVION	NNP	O
per	IN	O
kg	NN	O
body	NN	O
weight	VBD	O
every	DT	O
7	CD	O
days	NNS	O
,	,	O
or	CC	O
50	CD	DOS
to	TO	O
75	CD	DOS
IU	NNP	UNIT
of	IN	O
IDELVION	NNP	O
per	IN	O
kg	NN	O
every	DT	O
14	CD	O
days	NNS	O
0	0	O
		
IFEX	NNP	O
(	(	O
ifosfamide	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
intravenously	RB	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
1.2	CD	DOS
g/m??	NNS	UNIT
per	IN	O
day	NN	O
for	IN	O
5	CD	O
consecutive	JJ	O
days	NNS	O
0	0	O
		
One	CD	DOS
drop	NN	UNIT
of	IN	O
ILEVRO	NNP	O
(	(	O
nepafenac	JJ	O
ophthalmic	JJ	O
suspension	NN	O
)	)	O
,	,	O
0.3	CD	O
%	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
eye	NN	O
one-time-daily	RB	O
beginning	VBG	O
1	CD	O
day	NN	O
prior	RB	O
to	TO	O
cataract	VB	O
surgery	NN	O
,	,	O
continued	VBD	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
surgery	NN	O
and	CC	O
through	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
IMBRUVICA	NNP	O
for	IN	O
MCL	NNP	O
is	VBZ	O
560	CD	DOS
mg	NN	UNIT
(	(	O
four	CD	DOS
140	CD	O
mg	NN	O
capsules	NNS	UNIT
)	)	O
orally	RB	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
IMDUR	NNP	O
Tablets	NNP	O
is	VBZ	O
30	CD	DOS
mg	NN	UNIT
(	(	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
30	CD	DOS
mg	JJ	UNIT
tablet	NN	UNIT
or	CC	O
as	IN	O
1/2	CD	DOS
of	IN	O
a	DT	O
60	CD	DOS
mg	JJ	UNIT
tablet	NN	UNIT
)	)	O
or	CC	O
60	CD	DOS
mg	NN	UNIT
(	(	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
tablet	NN	UNIT
)	)	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
maximum	JJ	O
single	JJ	O
recommended	VBN	O
adult	NN	O
dose	NN	O
of	IN	O
IMITREX	NNP	O
Injection	NNP	O
for	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	O
or	CC	O
cluster	NN	O
headache	NN	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
injected	VBD	O
subcutaneously	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
subsequent	JJ	O
administrations	NNS	O
is	VBZ	O
up	IN	O
to	TO	O
4	CD	DOS
mL	NN	UNIT
of	IN	O
IMLYGIC	NNP	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
108	CD	O
(	(	O
100	CD	O
million	CD	O
)	)	O
PFU	NNP	O
per	IN	O
mL	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
INCIVEK	NNP	O
tablets	NNS	O
is	VBZ	O
1125	CD	DOS
mg	NN	UNIT
(	(	O
three	CD	DOS
375-mg	JJ	O
tablets	NNS	UNIT
)	)	O
taken	VBN	O
orally	RB	O
twice	JJ	O
daily	RB	O
(	(	O
10-14	JJ	O
hours	NNS	O
apart	RB	O
)	)	O
with	IN	O
food	NN	O
(	(	O
not	RB	O
low	JJ	O
fat	NN	O
)	)	O
0	0	O
		
The	DT	O
recommended	JJ	O
daily	JJ	O
dosage	NN	O
is	VBZ	O
180	CD	DOS
mg	NN	UNIT
to	TO	O
240	CD	DOS
mg	NNS	UNIT
Inderal	JJ	O
per	IN	O
day	NN	O
in	IN	O
divided	JJ	O
doses	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
initial	JJ	O
dosage	NN	O
is	VBZ	O
80	CD	DOS
mg	JJ	UNIT
Inderal	NNP	O
LA	NNP	O
once	RB	O
daily	RB	O
,	,	O
whether	IN	O
used	VBN	O
alone	RB	O
or	CC	O
added	VBN	O
to	TO	O
a	DT	O
diuretic	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
INFLECTRA	NNP	O
is	VBZ	O
5	CD	DOS
mg/kg	NN	UNIT
given	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
induction	NN	O
regimen	NNS	O
at	IN	O
0	CD	O
,	,	O
2	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
regimen	NN	O
of	IN	O
5	CD	DOS
mg/kg	NN	UNIT
every	DT	O
6	CD	O
weeks	NNS	O
thereafter	RB	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
active	JJ	O
ankylosing	VBG	O
spondylitis	NN	O
0	0	O
		
For	IN	O
management	NN	O
of	IN	O
bronchial	JJ	O
asthma	NN	O
in	IN	O
adults	NNS	O
and	CC	O
pediatric	JJ	O
patients	NNS	O
(	(	O
two	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
over	IN	O
)	)	O
,	,	O
the	DT	O
usual	JJ	O
starting	NN	O
dosage	NN	O
is	VBZ	O
the	DT	O
contents	NNS	O
of	IN	O
one	CD	DOS
ampule	NN	UNIT
administered	VBN	O
by	IN	O
nebulization	NN	O
four	CD	O
times	NNS	O
a	DT	O
day	NN	O
at	IN	O
regular	JJ	O
intervals	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
duration	NN	O
of	IN	O
treatment	NN	O
for	IN	O
patients	NNS	O
previously	RB	O
untreated	VBN	O
with	IN	O
interferon	NN	O
is	VBZ	O
24	CD	O
to	TO	O
48	CD	O
weeks	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
INVEGA??	NNP	O
(	(	O
paliperidone	NN	O
)	)	O
Extended-Release	NNP	O
Tablets	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
schizophrenia	NN	O
in	IN	O
adults	NNS	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
administered	VBN	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	JJ	O
initiation	NN	O
of	IN	O
INVEGA	NNP	O
SUSTENNA??	NNP	O
is	VBZ	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
234	CD	DOS
mg	NNS	UNIT
on	IN	O
treatment	NN	O
day	NN	O
1	CD	O
and	CC	O
156	CD	DOS
mg	NN	UNIT
one	CD	O
week	NN	O
later	RB	O
,	,	O
both	DT	O
administered	VBN	O
in	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
0	0	O
		
IPLEX	NNP	O
(	(	O
mecasermin	JJ	O
rinfabate	NN	O
[	NNP	O
rdna	NN	O
origin	NN	O
]	NNP	O
injection	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
via	IN	O
subcutaneous	JJ	O
injection	NN	O
at	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mg/kg	NNS	UNIT
,	,	O
to	TO	O
be	VB	O
increased	VBN	O
into	IN	O
the	DT	O
therapeutic	JJ	O
dose	NN	O
range	NN	O
of	IN	O
1	CD	DOS
to	TO	O
2	CD	DOS
mg/kg	NN	UNIT
,	,	O
given	VBN	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
IRESSA	NNP	O
is	VBZ	O
250	CD	DOS
mg	NN	UNIT
orally	RB	O
once	RB	O
daily	JJ	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
0	0	O
		
One	CD	DOS
drop	NN	UNIT
of	IN	O
Isopto??	NNP	O
Carpine	NNP	O
1	CD	O
%	NN	O
,	,	O
2	CD	O
%	NN	O
or	CC	O
4	CD	O
%	NN	O
should	MD	O
be	VB	O
applied	VBN	O
topically	RB	O
in	IN	O
the	DT	O
eye	NN	O
(	(	O
s	NN	O
)	)	O
up	IN	O
to	TO	O
four	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
romidepsin	NN	O
is	VBZ	O
14	CD	DOS
mg/m2	NN	UNIT
administered	VBD	O
intravenously	RB	O
over	IN	O
a	DT	O
4-hour	JJ	O
period	NN	O
on	IN	O
days	NNS	O
1	CD	O
,	,	O
8	CD	O
,	,	O
and	CC	O
15	CD	O
of	IN	O
a	DT	O
28-day	JJ	O
cycle	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
IXEMPRA	NNP	O
is	VBZ	O
40	CD	DOS
mg/m??	NN	UNIT
administered	VBD	O
intravenously	RB	O
over	IN	O
3	CD	O
hours	NNS	O
every	DT	O
3	CD	O
weeks	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
JARDIANCE	NNP	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
in	IN	O
the	DT	O
morning	NN	O
,	,	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
0	0	O
		
Initiate	NNP	O
treatment	NN	O
with	IN	O
one	CD	DOS
0.1	CD	O
mg	NN	O
tablet	NN	UNIT
at	IN	O
bedtime	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
dietary	JJ	O
potassium	NN	O
intake	NN	O
by	IN	O
the	DT	O
average	JJ	O
adult	NN	O
is	VBZ	O
50	CD	DOS
to	TO	O
100	CD	DOS
mEq	NNS	UNIT
per	IN	O
day	NN	O
0	0	O
		
The	DT	O
range	NN	O
of	IN	O
initial	JJ	O
doses	NNS	O
is	VBZ	O
0.11	CD	DOS
to	TO	O
1.6	CD	DOS
mg/kg/day	NN	UNIT
in	IN	O
3	CD	O
or	CC	O
4	CD	O
divided	VBN	O
doses	NNS	O
(	(	O
3.2	CD	DOS
to	TO	O
48	CD	DOS
mg/m??bsa/day	NN	UNIT
)	)	O
0	0	O
		
Initiate	NNP	O
treatment	NN	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
1000	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
Initiate	NNP	O
dosing	NN	O
at	IN	O
50	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Kineret	NNP	O
is	VBZ	O
1-2	JJ	DOS
mg/kg	NN	UNIT
for	IN	O
NOMID	NNP	O
patients	NNS	O
0	0	O
		
KYBELLA	NNP	O
is	VBZ	O
injected	VBN	O
into	IN	O
subcutaneous	JJ	O
fat	JJ	O
tissue	NN	O
in	IN	O
the	DT	O
submental	JJ	O
area	NN	O
using	VBG	O
an	DT	O
area-adjusted	JJ	O
dose	NN	O
of	IN	O
2	CD	DOS
mg/cm??	NN	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Kyprolis	NNP	O
is	VBZ	O
20	CD	DOS
mg/m2	NN	UNIT
in	IN	O
Cycle	NNP	O
1	CD	O
on	IN	O
Days	NNS	O
1	CD	O
and	CC	O
2	CD	O
0	0	O
		
The	DT	O
recommended	VBN	O
adult	NN	O
dosage	NN	O
of	IN	O
oral	JJ	O
KYTRIL	NNP	O
(	(	O
granisetron	NNP	O
hydrochloride	NN	O
)	)	O
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
once	RB	O
daily	JJ	O
or	CC	O
1	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
0	0	O
		
Toenail	JJ	O
onychomycosis	NN	O
:	:	O
One	CD	DOS
250	CD	O
mg	NN	O
tablet	NN	UNIT
once	RB	O
daily	JJ	O
for	IN	O
12	CD	O
weeks	NNS	O
0	0	O
		
For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
proven	JJ	O
dapsone-resistant	JJ	O
leprosy	NN	O
,	,	O
Lamprene	NNP	O
(	(	O
clofazimine	NN	O
)	)	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
100	CD	DOS
mg	JJ	UNIT
daily	RB	O
in	IN	O
combination	NN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
other	JJ	O
antileprosy	JJ	O
drugs	NNS	O
for	IN	O
3	CD	O
years	NNS	O
,	,	O
followed	VBN	O
by	IN	O
monotherapy	NN	O
with	IN	O
100	CD	DOS
mg	NNS	UNIT
of	IN	O
Lamprene	NNP	O
(	(	O
clofazimine	NN	O
)	)	O
daily	RB	O
0	0	O
		
The	DT	O
usual	JJ	O
starting	NN	O
and	CC	O
maintenance	NN	O
dose	NN	O
of	IN	O
levatol??	NN	O
,	,	O
used	VBD	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antihypertensive	JJ	O
agents	NNS	O
,	,	O
such	JJ	O
as	IN	O
thiazide-type	JJ	O
diuretics	NNS	O
,	,	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
given	VBN	O
once	RB	O
daily	JJ	O
0	0	O
		
Initiate	NNP	O
treatment	NN	O
with	IN	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
1000	CD	DOS
mg/day	NN	UNIT
,	,	O
given	VBN	O
as	IN	O
twice-daily	JJ	O
dosing	NN	O
(	(	O
500	CD	DOS
mg	NN	UNIT
twice	RB	O
daily	RB	O
)	)	O
0	0	O
		
The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
for	IN	O
oral	JJ	O
administration	NN	O
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
0	0	O
		
7	CD	DOS
mcg/kg/day	NN	UNIT
(	(	O
e.	JJ	O
g.	NN	O
,	,	O
100-125	JJ	DOS
mcg/day	NN	UNIT
for	IN	O
a	DT	O
70	CD	O
kg	NN	O
adult	NN	O
)	)	O
0	0	O
		
Adults	NNS	O
and	CC	O
pediatric	JJ	O
patients	NNS	O
12	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
older	JJR	O
:	:	O
1	CD	DOS
to	TO	O
2	CD	DOS
tablets	NNS	UNIT
every	DT	O
four	CD	O
hours	NNS	O
or	CC	O
as	IN	O
needed	VBN	O
0	0	O
		
A	DT	O
1000	CD	DOS
second	NN	UNIT
(	(	O
16	CD	O
minutes	NNS	O
40	CD	O
seconds	NNS	O
)	)	O
exposure	NN	O
is	VBZ	O
required	VBN	O
to	TO	O
provide	VB	O
a	DT	O
10	CD	O
J/cm??	NNP	O
light	NN	O
dose	NN	O
0	0	O
		
For	IN	O
the	DT	O
clinical	JJ	O
dietary	JJ	O
management	NN	O
of	IN	O
the	DT	O
metabolic	JJ	O
processes	NNS	O
of	IN	O
OA	NNP	O
,	,	O
take	VBP	O
either	DT	O
one	CD	DOS
250	CD	O
mg	NN	O
or	CC	O
one	CD	DOS
500	CD	O
mg	NN	O
capsule	NN	UNIT
every	DT	O
12	CD	O
hours	NNS	O
for	IN	O
500	CD	DOS
mg	NNS	UNIT
to	TO	O
1000	CD	DOS
mg	NNS	UNIT
total	JJ	O
daily	JJ	O
consumption	NN	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
LIPITOR	NNP	O
is	VBZ	O
10	CD	DOS
or	CC	O
20	CD	DOS
mg	NNS	UNIT
once	RB	O
daily	RB	O
0	0	O
		
The	DT	O
dosage	NN	O
range	NN	O
of	IN	O
LIPTRUZET	NNP	O
is	VBZ	O
10/10	CD	DOS
mg/day	NN	UNIT
to	TO	O
10/80	CD	DOS
mg/day	NN	UNIT
0	0	O
		
The	DT	O
dose	JJ	O
range	NN	O
for	IN	O
LIVALO	NNP	O
is	VBZ	O
1	CD	DOS
to	TO	O
4	CD	DOS
mg	NNS	UNIT
orally	RB	O
once	RB	O
daily	JJ	O
at	IN	O
any	DT	O
time	NN	O
of	IN	O
the	DT	O
day	NN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
0	0	O
		
The	DT	O
initial	JJ	O
dosage	NN	O
is	VBZ	O
0.2	CD	DOS
mg/kg	NN	UNIT
minoxidil	NN	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	O
dose	NN	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
adults	NNS	O
is	VBZ	O
1200	CD	DOS
mg	NN	UNIT
administered	VBN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
30	CD	O
minutes	NNS	O
before	IN	O
the	DT	O
morning	NN	O
and	CC	O
evening	NN	O
meals	NNS	O
0	0	O
		
In	IN	O
patients	NNS	O
who	WP	O
tolerate	VBP	O
the	DT	O
full	JJ	O
intravenous	JJ	O
dose	NN	O
(	(	O
15	CD	DOS
mg	NN	UNIT
)	)	O
,	,	O
initiate	JJ	O
Lopressor	NNP	O
tablets	NNS	O
,	,	O
50	CD	DOS
mg	NN	UNIT
every	DT	O
6	CD	O
hours	NNS	O
,	,	O
15	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
last	JJ	O
intravenous	JJ	O
dose	NN	O
and	CC	O
continue	VB	O
for	IN	O
48	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
every	DT	O
four	CD	O
to	TO	O
six	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablespoonful	NN	UNIT
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
0	0	O
		
Usual	JJ	O
Dosage	NNP	O
in	IN	O
Adults	NNP	O
:	:	O
To	TO	O
lower	VB	O
the	DT	O
risk	NN	O
of	IN	O
constipation	NN	O
,	,	O
LOTRONEX	NNP	O
(	(	O
alosetron	VB	O
hydrochloride	NN	O
)	)	O
should	MD	O
be	VB	O
started	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
0.5	CD	DOS
mg	NN	UNIT
twice	RB	O
a	DT	O
day	NN	O
0	0	O
		
The	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
LOVAZA	NNP	O
is	VBZ	O
4	CD	DOS
grams	NNS	UNIT
per	IN	O
day	NN	O
0	0	O
		
The	DT	O
initial	JJ	O
course	NN	O
of	IN	O
treatment	NN	O
with	IN	O
leuprolide	JJ	O
acetate	NN	O
for	IN	O
depot	NN	O
suspension	NN	O
3.75	CD	O
mg	NN	O
in	IN	O
combination	NN	O
with	IN	O
norethindrone	JJ	O
acetate	NN	O
5	CD	O
mg	JJ	O
daily	RB	O
is	VBZ	O
not	RB	O
to	TO	O
exceed	VB	O
six	CD	O
months	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
LUPRON	NNP	O
DEPOT	NNP	O
22.5	CD	O
mg	NN	O
for	IN	O
3-month	JJ	O
administration	NN	O
is	VBZ	O
one	CD	DOS
injection	NN	UNIT
every	DT	O
12	CD	O
weeks	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
LUPRON	NNP	O
DEPOT	NNP	O
is	VBZ	O
3.75	CD	DOS
mg	NN	UNIT
,	,	O
incorporated	VBN	O
in	IN	O
a	DT	O
depot	NN	O
formulation	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
LUPRON	NNP	O
DEPOT	NNP	O
is	VBZ	O
7.5	CD	DOS
mg	NN	UNIT
for	IN	O
1-month	JJ	O
administration	NN	O
,	,	O
incorporated	VBN	O
in	IN	O
a	DT	O
depot	NN	O
formulation	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
dose	NN	O
for	IN	O
adults	NNS	O
and	CC	O
children	NNS	O
12	CD	O
years	NNS	O
and	CC	O
older	JJR	O
is	VBZ	O
two	CD	DOS
inhalations	NNS	UNIT
(	(	O
400	CD	DOS
mcg	NN	UNIT
)	)	O
repeated	VBD	O
every	DT	O
4-6	JJ	O
hours	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
MAXZIDE-25	NNP	O
MG	NNP	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
daily	RB	O
,	,	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
,	,	O
with	IN	O
appropriate	JJ	O
monitoring	NN	O
of	IN	O
serum	JJ	O
potassium	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
adult	NN	O
dose	NN	O
,	,	O
after	IN	O
reconstitution	NN	O
with	IN	O
oxidant-free	JJ	O
sodium	NN	O
pertechnetate	NN	O
Tc	NNP	O
99m	CD	O
,	,	O
is	VBZ	O
370	CD	DOS
to	TO	O
740	CD	DOS
megabecquerels	NNS	UNIT
(	(	O
10	CD	DOS
to	TO	O
20	CD	DOS
millicuries	NNS	UNIT
[	VBP	O
200	CD	DOS
??Ci/kg	NNP	UNIT
]	NN	O
)	)	O
by	IN	O
slow	JJ	O
intravenous	JJ	O
injection	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
30	CD	O
seconds	NNS	O
0	0	O
		
The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
meclizine	JJ	O
hydrochloride	NN	O
,	,	O
should	MD	O
be	VB	O
taken	VBN	O
one	CD	O
hour	NN	O
prior	RB	O
to	TO	O
travel	VB	O
for	IN	O
protection	NN	O
against	IN	O
motion	NN	O
sickness	NN	O
0	0	O
		
Breast	NNP	O
cancer	NN	O
:	:	O
160	CD	DOS
mg/day	NN	UNIT
(	(	O
40	CD	DOS
mg	NN	UNIT
q.i.d	NN	O
0	0	O
		
)	)	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
MENOPUR??	NNP	O
for	IN	O
women	NNS	O
who	WP	O
have	VBP	O
received	VBN	O
a	DT	O
GnRH	NNP	O
agonist	NN	O
for	IN	O
pituitary	JJ	O
suppression	NN	O
is	VBZ	O
225	CD	DOS
International	NNP	UNIT
Units	NNP	UNIT
0	0	O
		
Each	DT	O
MENVEO	NNP	O
dose	NN	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
0.5	CD	DOS
mL	NN	UNIT
intramuscular	JJ	O
injection	NN	UNIT
,	,	O
preferably	RB	O
into	IN	O
the	DT	O
anterolateral	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
thigh	NN	O
in	IN	O
infants	NNS	O
or	CC	O
into	IN	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
(	(	O
upper	JJ	O
arm	NN	O
)	)	O
in	IN	O
toddlers	NNS	O
,	,	O
adolescents	NNS	O
and	CC	O
adults	NNS	O
0	0	O
		
0.1	CD	DOS
to	TO	O
0.2	CD	DOS
mL	NNS	UNIT
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	NN	O
(	(	O
0.045	CD	DOS
to	TO	O
0.09	CD	DOS
mL	NNS	UNIT
per	IN	O
pound	NN	O
of	IN	O
body	NN	O
weight	NN	O
)	)	O
0	0	O
		
Average	JJ	O
dosage	NN	O
is	VBZ	O
20	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
daily	RB	O
0	0	O
		
15	CD	DOS
mg/kg	NNS	UNIT
orally	RB	O
every	DT	O
4	CD	O
hours	NNS	O
for	IN	O
6	CD	O
doses	NNS	O
0	0	O
		
Take	VB	O
10	CD	DOS
mg	NNS	UNIT
to	TO	O
15	CD	DOS
mg	NNS	UNIT
dose	NN	O
of	IN	O
METOZOLV	NNP	O
ODT	NNP	O
up	RB	O
to	TO	O
four	CD	O
times	NNS	O
daily	RB	O
(	(	O
e.g.	NN	O
,	,	O
at	IN	O
least	JJS	O
30	CD	O
minutes	NNS	O
before	IN	O
each	DT	O
meal	NN	O
and	CC	O
at	IN	O
bedtime	NN	O
)	)	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
applicator	NN	UNIT
full	JJ	O
of	IN	O
METROGEL-VAGINAL	NNP	O
(	(	O
approximately	RB	O
5	CD	O
grams	NNS	O
containing	VBG	O
approximately	RB	O
37.5	CD	O
mg	NNS	O
of	IN	O
metronidazole	NN	O
)	)	O
intravaginally	RB	O
once	RB	O
or	CC	O
twice	VB	O
a	DT	O
day	NN	O
for	IN	O
5	CD	O
days	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
MICRONASE	NNP	O
Tablets	NNP	O
is	VBZ	O
2.5	CD	DOS
to	TO	O
5	CD	DOS
mg	NNS	UNIT
daily	RB	O
,	,	O
administered	VBN	O
with	IN	O
breakfast	NN	O
or	CC	O
the	DT	O
first	JJ	O
main	JJ	O
meal	NN	O
0	0	O
		
For	IN	O
Control	NNP	O
of	IN	O
Hypertension	NNP	O
:	:	O
The	DT	O
adult	NN	O
initial	JJ	O
dose	NN	O
of	IN	O
MICROZIDE	NNP	O
(	(	O
hydrochlorothiazide	JJ	O
capsule	NN	O
)	)	O
is	VBZ	O
one	CD	DOS
capsule	NN	UNIT
given	VBN	O
once	RB	O
daily	JJ	O
whether	IN	O
given	VBN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antihypertensives	NNS	O
0	0	O
		
Usual	JJ	O
pediatric	JJ	O
dose	NN	O
:	:	O
Initial	JJ	O
dose	NN	O
of	IN	O
4	CD	DOS
mg/kg	NNS	UNIT
,	,	O
then	RB	O
2	CD	DOS
mg/kg	NNS	UNIT
every	DT	O
12	CD	O
hours	NNS	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
the	DT	O
usual	JJ	O
adult	NN	O
dose	JJ	O
Usual	NNP	O
adult	NN	O
dose	NN	O
:	:	O
Initial	JJ	O
dose	NN	O
of	IN	O
200	CD	DOS
mg	NNS	UNIT
,	,	O
then	RB	O
100	CD	DOS
mg	NNS	UNIT
every	DT	O
12	CD	O
hours	NNS	O
and	CC	O
should	MD	O
not	RB	O
exceed	VB	O
400	CD	O
mg	NNS	O
in	IN	O
24	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
maximum	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
MINTEZOL	NNP	O
(	(	O
thiabendazole	NN	O
)	)	O
is	VBZ	O
3	CD	DOS
grams	NNS	UNIT
0	0	O
		
Initial	JJ	O
dosage	NN	O
of	IN	O
MIRADON	NNP	O
(	(	O
anisindione	NN	O
)	)	O
Tablets	NNPS	O
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
the	DT	O
first	JJ	O
day	NN	O
,	,	O
200	CD	DOS
mg	VBD	UNIT
the	DT	O
second	JJ	O
day	NN	O
,	,	O
and	CC	O
100	CD	DOS
mg	NN	UNIT
the	DT	O
third	JJ	O
day	NN	O
0	0	O
		
Treatment	NN	O
of	IN	O
Testicular	JJ	O
Tumors	NNS	O
:	:	O
In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
testicular	JJ	O
tumors	NNS	O
the	DT	O
recommended	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
Mithracin	NNP	O
(	(	O
plicamycin	NN	O
)	)	O
is	VBZ	O
25	CD	DOS
to	TO	O
30	CD	DOS
mcg	NNS	UNIT
(	(	O
0.025-0.030	JJ	DOS
mg	NN	UNIT
)	)	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	NN	O
0	0	O
		
The	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
1.2	CD	DOS
mg	JJ	UNIT
per	IN	O
day	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
MOVANTIK	NNP	O
dosage	NN	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
in	IN	O
the	DT	O
morning	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
troche	NN	UNIT
five	CD	O
times	NNS	O
a	DT	O
day	NN	O
for	IN	O
fourteen	JJ	O
consecutive	JJ	O
days	NNS	O
0	0	O
		
It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
MYCOBUTIN	NNP	O
Capsules	NNP	O
be	VB	O
administered	VBN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
300	CD	DOS
mg	NNS	UNIT
once	RB	O
daily	RB	O
0	0	O
		
Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
NAFTIN	NNP	O
Cream	NNP	O
once-daily	RB	O
to	TO	O
the	DT	O
affected	JJ	O
areas	NNS	O
plus	CC	O
a	DT	O
??	JJ	O
inch	NN	O
margin	NN	O
of	IN	O
healthy	JJ	O
surrounding	VBG	O
skin	NN	O
for	IN	O
2	CD	O
weeks	NNS	O
0	0	O
		
A	DT	O
dose	NN	O
of	IN	O
50	CD	DOS
mg	NNS	UNIT
once	RB	O
daily	JJ	O
is	VBZ	O
recommended	VBN	O
for	IN	O
most	JJS	O
patients	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
NARDIL	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
(	(	O
15	CD	DOS
mg	NN	UNIT
)	)	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
0	0	O
		
For	IN	O
adults	NNS	O
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
NASAREL	NNP	O
is	VBZ	O
2	CD	DOS
sprays	NNS	UNIT
(	(	O
58	CD	DOS
mcg	NN	UNIT
)	)	O
in	IN	O
each	DT	O
nostril	NN	O
2	CD	O
times	NNS	O
a	DT	O
day	NN	O
(	(	O
total	JJ	O
dose	RB	O
232	CD	DOS
mcg/day	NN	UNIT
)	)	O
:	:	O
the	DT	O
effect	NN	O
should	MD	O
be	VB	O
assessed	VBN	O
in	IN	O
4	CD	O
to	TO	O
7	CD	O
days	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
Nascobal	NNP	O
(	(	O
cyanocobalamin	NN	O
)	)	O
Nasal	NNP	O
Spray	NNP	O
is	VBZ	O
one	CD	DOS
spray	NN	UNIT
(	(	O
500	CD	DOS
mcg	NN	UNIT
)	)	O
administered	VBD	O
in	IN	O
ONE	CD	O
nostril	NN	O
once	RB	O
weekly	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
NATRECOR??	NNP	O
is	VBZ	O
an	DT	O
IV	NNP	O
bolus	NN	O
of	IN	O
2	CD	O
mcg/kg	NN	O
followed	VBN	O
by	IN	O
a	DT	O
continuous	JJ	O
infusion	NN	O
of	IN	O
0.01	CD	O
mcg/kg/min	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Neulasta	NNP	O
is	VBZ	O
a	DT	O
single	JJ	DOS
subcutaneous	JJ	UNIT
injection	NN	UNIT
of	IN	O
6	CD	O
mg	NNS	O
administered	VBN	O
once	RB	O
per	IN	O
chemotherapy	NN	O
cycle	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
NEXAVAR	NNP	O
is	VBZ	O
400	CD	DOS
mg	NN	UNIT
(	(	O
2	CD	DOS
x	RB	O
200	CD	DOS
mg	JJ	O
tablets	NNS	UNIT
)	)	O
taken	VBN	O
twice	RB	O
daily	RB	O
without	IN	O
food	NN	O
(	(	O
at	IN	O
least	JJS	O
1	CD	O
hour	NN	O
before	IN	O
or	CC	O
2	CD	O
hours	NNS	O
after	IN	O
a	DT	O
meal	NN	O
)	)	O
0	0	O
		
Adults	NNS	O
:	:	O
1	CD	DOS
or	CC	O
2	CD	DOS
capsules	NNS	UNIT
twice	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
once	RB	O
a	DT	O
day	NN	O
for	IN	O
30	CD	O
days	NNS	O
,	,	O
followed	VBD	O
thereafter	RB	O
by	IN	O
150	CD	DOS
mg	NN	UNIT
once	RB	O
a	DT	O
day	NN	O
0	0	O
		
A	DT	O
dosage	NN	O
of	IN	O
0.024	CD	DOS
to	TO	O
0.034	CD	DOS
mg/kg/day	NN	UNIT
,	,	O
6	CD	O
to	TO	O
7	CD	O
times	NNS	O
a	DT	O
week	NN	O
,	,	O
is	VBZ	O
recommended	VBN	O
0	0	O
		
Apply	NNP	O
and	CC	O
rub	NN	O
in	IN	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
NORITATE	NNP	O
(	(	O
metronidazole	NN	O
)	)	O
once	RB	O
daily	JJ	O
to	TO	O
entire	JJ	O
affected	JJ	O
area	NN	O
(	(	O
s	NN	O
)	)	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dosage	NN	O
of	IN	O
Norpace	NNP	O
(	(	O
disopyramide	JJ	O
phosphate	NN	O
)	)	O
or	CC	O
Norpace	NNP	O
(	(	O
disopyramide	JJ	O
phosphate	NN	O
)	)	O
CR	NNP	O
is	VBZ	O
400	CD	DOS
to	TO	O
800	CD	DOS
mg	NNS	UNIT
per	IN	O
day	NN	O
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dose	NN	O
is	VBZ	O
100	CD	DOS
to	TO	O
200	CD	DOS
mg	NNS	UNIT
per	IN	O
day	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
initial	JJ	O
antihypertensive	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
NORVASC	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	O
daily	JJ	O
,	,	O
and	CC	O
the	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
For	IN	O
intravenous	JJ	O
use	NN	O
,	,	O
Novolin	NNP	O
R	NNP	O
should	MD	O
be	VB	O
used	VBN	O
at	IN	O
concentrations	NNS	O
from	IN	O
0.05	CD	DOS
units/mL	NNS	UNIT
to	TO	O
1	CD	DOS
unit/mL	NNS	UNIT
in	IN	O
infusion	NN	O
systems	NNS	O
using	VBG	O
polypropylene	JJ	O
infusion	NN	O
bags	NNS	O
0	0	O
		
10	CD	DOS
mL	NN	UNIT
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
6	CD	O
doses	NNS	O
(	(	O
60	CD	O
mL	NN	O
)	)	O
in	IN	O
24	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ODEFSEY	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
with	IN	O
a	DT	O
meal	NN	O
in	IN	O
the	DT	O
following	JJ	O
patient	JJ	O
population	NN	O
:	:	O
adults	NNS	O
and	CC	O
in	IN	O
pediatric	JJ	O
patients	NNS	O
12	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
older	JJR	O
with	IN	O
body	NN	O
weight	NN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
35	CD	O
kg	NNS	O
and	CC	O
a	DT	O
creatinine	JJ	O
clearance	NN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
30	CD	O
mL	NNS	O
per	IN	O
minute	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
adult	NN	O
dose	NN	O
of	IN	O
Oforta?"?	NNP	O
(	(	O
fludarabine	JJ	O
phosphate	NN	O
tablets	NNS	O
)	)	O
is	VBZ	O
40	CD	DOS
mg/m	NN	UNIT
administered	VBN	O
by	IN	O
mouth	JJ	O
daily	JJ	O
for	IN	O
five	CD	O
consecutive	JJ	O
days	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Oleptro	NNP	O
is	VBZ	O
150	CD	DOS
mg	NN	UNIT
once	RB	O
daily	JJ	O
in	IN	O
adults	NNS	O
0	0	O
		
Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
Olux-E	NNP	O
(	(	O
clobetasol	JJ	O
propionate	NN	O
foam	NN	O
)	)	O
Foam	NNP	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
(	(	O
s	PRP	O
)	)	O
twice	RB	O
daily	RB	O
,	,	O
morning	NN	O
and	CC	O
evening	NN	O
for	IN	O
up	IN	O
to	TO	O
2	CD	O
consecutive	JJ	O
weeks	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
OLYSIO	NNP	O
is	VBZ	O
one	CD	DOS
150	CD	O
mg	NN	O
capsule	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
with	IN	O
food	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
OPDIVO	NNP	O
is	VBZ	O
240	CD	DOS
mg	NN	UNIT
administered	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
60	CD	O
minutes	NNS	O
every	DT	O
2	CD	O
weeks	NNS	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
OptiPranolol	NNP	O
(	(	O
metipranolol	JJ	O
ophthalmic	JJ	O
solution	NN	O
)	)	O
Ophthalmic	NNP	O
Solution	NNP	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
twice	RB	O
a	DT	O
day	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosing	NN	O
for	IN	O
ORBACTIV	NNP	O
is	VBZ	O
a	DT	O
single	JJ	DOS
1200	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
administered	VBN	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
3	CD	O
hours	NNS	O
in	IN	O
patients	NNS	O
18	CD	O
years	NNS	O
and	CC	O
older	JJR	O
0	0	O
		
1	CD	DOS
or	CC	O
2	CD	DOS
capsules	NNS	UNIT
every	DT	O
4	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Orenitram	NNP	O
is	VBZ	O
0.25	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
(	(	O
BID	NNP	O
)	)	O
with	IN	O
food	NN	O
,	,	O
taken	VBN	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
or	CC	O
0.125	CD	DOS
mg	NNS	UNIT
three	CD	O
times	NNS	O
daily	RB	O
(	(	O
TID	NNP	O
)	)	O
with	IN	O
food	NN	O
,	,	O
taken	VBN	O
approximately	RB	O
8	CD	O
hours	NNS	O
apart	RB	O
0	0	O
		
INJECTION	NN	O
:	:	O
Adults	NNP	O
-	:	O
One	CD	DOS
2	CD	O
mL	NN	O
vial	NN	UNIT
(	(	O
60	CD	DOS
mg	NN	UNIT
)	)	O
intravenously	RB	O
or	CC	O
intramuscularly	RB	O
;	:	O
may	MD	O
be	VB	O
repeated	VBN	O
every	DT	O
12	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
Oxtellar	NNP	O
XR??	NNP	O
is	VBZ	O
1200	CD	DOS
mg	NN	UNIT
to	TO	O
2400	CD	DOS
mg	NNS	UNIT
per	IN	O
day	NN	O
,	,	O
given	VBN	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Pamidronate	NNP	O
disodium	NN	O
for	IN	O
Injection	NNP	O
USP	NNP	O
in	IN	O
severe	JJ	O
hypercalcemia	NN	O
(	(	O
corrected	VBN	O
serum	NN	O
calcium*	NN	O
>	VBD	O
13.5	CD	O
mg/dL	NN	O
)	)	O
is	VBZ	O
90	CD	DOS
mg	NN	UNIT
given	VBN	O
as	IN	O
a	DT	O
SINGLE-DOSE	NNP	DOS
,	,	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
2	CD	O
to	TO	O
24	CD	O
hours	NNS	O
0	0	O
		
Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
PANDEL	NNP	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
once	RB	O
or	CC	O
twice	VB	O
a	DT	O
day	NN	O
depending	VBG	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
0	0	O
		
Usual	JJ	O
Pediatric	NNP	O
Dosage	NN	O
:	:	O
0.25	CD	DOS
to	TO	O
0.5	CD	DOS
mL/kg	NN	UNIT
of	IN	O
body	NN	O
weight	VBD	O
1	CD	O
to	TO	O
4	CD	O
times	NNS	O
a	DT	O
day	NN	O
0	0	O
		
The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
Parlodel	NNP	O
SnapTabs??	NNP	O
in	IN	O
adults	NNS	O
is	VBZ	O
??	JJ	DOS
to	TO	O
one	CD	DOS
2??	CD	O
mg	NN	O
scored	VBD	O
tablet	JJ	UNIT
daily	JJ	O
0	0	O
		
The	DT	O
usual	JJ	O
dosage	NN	O
of	IN	O
PCE	NNP	O
tablets	NNS	O
are	VBP	O
one	CD	DOS
333	CD	O
mg	NN	O
tablet	NN	UNIT
every	DT	O
8	CD	O
hours	NNS	O
or	CC	O
one	CD	DOS
500	CD	O
mg	NN	O
tablet	NN	UNIT
every	DT	O
12	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
PEDIAPRED	NNP	O
(	(	O
prednisolone	JJ	O
sodium	NN	O
)	)	O
may	MD	O
vary	VB	O
from	IN	O
5	CD	DOS
mL	NNS	UNIT
to	TO	O
60	CD	DOS
mL	NN	UNIT
(	(	O
5	CD	DOS
to	TO	O
60	CD	DOS
mg	NN	UNIT
prednisolone	NN	O
base	NN	O
)	)	O
per	IN	O
day	NN	O
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
0	0	O
		
For	IN	O
adults	NNS	O
,	,	O
4	CD	DOS
drops	NNS	UNIT
of	IN	O
the	DT	O
suspension	NN	O
should	MD	O
be	VB	O
instilled	VBN	O
into	IN	O
the	DT	O
affected	JJ	O
ear	JJ	O
3	CD	O
or	CC	O
4	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
PEGANONE	NNP	O
(	(	O
ethotoin	JJ	O
tablets	NNS	O
,	,	O
USP	NNP	O
)	)	O
is	VBZ	O
administered	VBN	O
orally	RB	O
in	IN	O
4	CD	DOS
to	TO	O
6	CD	DOS
divided	JJ	UNIT
doses	NNS	O
daily	RB	O
0	0	O
		
Pentacel	NNP	O
vaccine	NN	O
is	VBZ	O
to	TO	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
4	CD	DOS
dose	JJ	UNIT
series	NN	O
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
and	CC	O
15-18	JJ	O
months	NNS	O
of	IN	O
age	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
adult	NN	O
oral	JJ	O
dosage	NN	O
for	IN	O
active	JJ	O
duodenal	JJ	O
ulcer	NN	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
once	RB	O
a	DT	O
day	NN	O
at	IN	O
bedtime	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
PERFOROMIST	NNP	O
(	(	O
formoterol	VB	O
fumarate	NN	O
)	)	O
Inhalation	NNP	O
Solution	NNP	O
is	VBZ	O
one	CD	DOS
20	CD	O
mcg	NN	O
unit-dose	JJ	O
vial	NN	UNIT
administered	VBD	O
twice	RB	O
daily	JJ	O
(	(	O
morning	NN	O
and	CC	O
evening	NN	O
)	)	O
by	IN	O
nebulization	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
PERIKABIVEN??	NNP	O
in	IN	O
adults	NNS	O
is	VBZ	O
27	CD	DOS
to	TO	O
40	CD	DOS
mL/kg/day	NN	UNIT
0	0	O
		
Administration	NN	O
of	IN	O
Permax	NNP	O
(	(	O
pergolide	JJ	O
mesylate	NN	O
)	)	O
should	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
a	DT	O
daily	JJ	O
dosage	NN	O
of	IN	O
0.05	CD	DOS
mg	NN	UNIT
for	IN	O
the	DT	O
first	JJ	O
2	CD	O
days	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
dosage	NN	O
of	IN	O
PIPRACIL	NNP	O
(	(	O
piperacillin	JJ	O
sodium	NN	O
)	)	O
for	IN	O
serious	JJ	O
infections	NNS	O
is	VBZ	O
3	CD	DOS
to	TO	O
4	CD	DOS
g	NNS	UNIT
given	VBN	O
every	DT	O
four	CD	O
to	TO	O
six	CD	O
hours	NNS	O
as	IN	O
a	DT	O
20-	JJ	O
to	TO	O
30-minute	JJ	O
infusion	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
PLATINOL	NNP	O
dose	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
testicular	JJ	O
cancer	NN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
approved	VBN	O
chemotherapeutic	JJ	O
agents	NNS	O
is	VBZ	O
20	CD	DOS
mg/m??	JJ	UNIT
IV	NNP	O
daily	NN	O
for	IN	O
5	CD	O
days	NNS	O
per	IN	O
cycle	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
PLETAL	NNP	O
is	VBZ	O
100	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
taken	VBN	O
at	IN	O
least	JJS	O
half	PDT	O
an	DT	O
hour	NN	O
before	IN	O
or	CC	O
two	CD	O
hours	NNS	O
after	IN	O
breakfast	NN	O
and	CC	O
dinner	NN	O
0	0	O
		
Apply	NNP	O
twice	JJ	O
daily	RB	O
morning	NN	O
and	CC	O
evening	NN	O
(	(	O
every	DT	O
12	CD	O
hours	NNS	O
)	)	O
,	,	O
for	IN	O
3	CD	O
consecutive	JJ	O
days	NNS	O
,	,	O
then	RB	O
withhold	VBD	O
use	NN	O
for	IN	O
4	CD	O
consecutive	JJ	O
days	NNS	O
0	0	O
		
TO	NNP	O
TREAT	NNP	O
THE	NNP	O
EYE	NNP	O
:	:	O
Instill	NNP	O
1	CD	DOS
or	CC	O
2	CD	DOS
drops	NNS	UNIT
every	DT	O
3	CD	O
or	CC	O
4	CD	O
hours	NNS	O
,	,	O
or	CC	O
more	RBR	O
frequently	RB	O
as	IN	O
required	VBN	O
0	0	O
		
The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
one	CD	DOS
20	CD	O
mg	NN	O
tablet	NN	UNIT
three	CD	O
times	NNS	O
daily	JJ	O
before	IN	O
meals	NNS	O
0	0	O
		
PrandiMet	NN	O
can	MD	O
be	VB	O
administered	VBN	O
2	CD	O
to	TO	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
up	RP	O
to	TO	O
a	DT	O
maximum	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
repaglinide/2500	VBP	O
mg	JJ	O
metformin	NN	O
HCl	NNP	O
0	0	O
		
Instill	NNP	O
one	CD	DOS
to	TO	O
two	CD	DOS
drops	NNS	UNIT
into	IN	O
the	DT	O
conjunctival	JJ	O
sac	NN	O
two	CD	O
to	TO	O
four	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
prednisolone	NN	O
sodium	NN	O
(	(	O
prednisolone	JJ	O
sodium	NN	O
phosphate	NN	O
oral	JJ	O
solution	NN	O
)	)	O
phosphate	NN	O
,	,	O
USP	NNP	O
,	,	O
oral	JJ	O
solution	NN	O
may	MD	O
vary	VB	O
from	IN	O
5	CD	DOS
mL	NNS	UNIT
to	TO	O
60	CD	DOS
mL	NN	UNIT
(	(	O
5	CD	DOS
to	TO	O
60	CD	DOS
mg	NN	UNIT
prednisolone	NN	O
base	NN	O
)	)	O
per	IN	O
day	NN	O
depending	VBG	O
on	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
entity	NN	O
being	VBG	O
treated	VBN	O
0	0	O
		
PREMPRO	NNP	O
therapy	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	DOS
tablet	NN	UNIT
to	TO	O
be	VB	O
taken	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
PRESTALIA	NNP	O
is	VBZ	O
3.5/2.5	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
For	IN	O
treatment	NN	O
of	IN	O
acute	JJ	O
episodes	NNS	O
of	IN	O
bronchospasm	NN	O
or	CC	O
prevention	NN	O
of	IN	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
bronchospasm	NN	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	O
and	CC	O
children	NNS	O
4	CD	O
years	NNS	O
of	IN	O
age	NN	O
or	CC	O
older	JJR	O
is	VBZ	O
2	CD	DOS
inhalations	NNS	UNIT
repeated	VBN	O
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
0	0	O
		
Apply	NNP	O
to	TO	O
affected	VB	O
area	NN	O
3	CD	O
to	TO	O
4	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
1	CD	DOS
to	TO	O
3	CD	DOS
mg	NNS	UNIT
administered	VBN	O
under	IN	O
careful	JJ	O
monitoring	NN	O
,	,	O
such	JJ	O
as	IN	O
electrocardiography	NN	O
and	CC	O
central	JJ	O
venous	JJ	O
pressure	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
for	IN	O
adults	NNS	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
at	IN	O
bedtime	NN	O
;	:	O
however	RB	O
,	,	O
some	DT	O
patients	NNS	O
may	MD	O
need	VB	O
a	DT	O
2	CD	DOS
mg	NN	UNIT
dose	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ProstaScint??	NNP	O
(	(	O
c	JJ	O
apromab	RB	O
pendetide	NN	O
)	)	O
is	VBZ	O
0.5	CD	DOS
mg	NN	UNIT
radiolabeled	VBD	O
with	IN	O
5	CD	DOS
mCi	NNS	UNIT
of	IN	O
Indium	NNP	O
In	IN	O
111	CD	O
chloride	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
course	NN	O
of	IN	O
therapy	NN	O
for	IN	O
PROVENGE	NNP	O
is	VBZ	O
3	CD	DOS
complete	JJ	O
doses	NNS	UNIT
,	,	O
given	VBN	O
at	IN	O
approximately	RB	O
2-week	JJ	O
intervals	NNS	O
0	0	O
		
PROVERA	NNP	O
tablets	NNS	O
may	MD	O
be	VB	O
given	VBN	O
in	IN	O
dosages	NNS	O
of	IN	O
5	CD	DOS
or	CC	O
10	CD	DOS
mg	NNS	UNIT
daily	RB	O
for	IN	O
5	CD	O
to	TO	O
10	CD	O
days	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
PROVIGIL	NNP	O
for	IN	O
patients	NNS	O
with	IN	O
narcolepsy	JJ	O
or	CC	O
OSA	NNP	O
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	O
a	DT	O
day	NN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
in	IN	O
the	DT	O
morning	NN	O
0	0	O
		
Adults	NNS	O
and	CC	O
children	NNS	O
12	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
older	JJR	O
:	:	O
One	CD	DOS
capsule	NN	UNIT
every	DT	O
12	CD	O
hours	NNS	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
2	CD	DOS
capsules	NNS	UNIT
in	IN	O
24	CD	O
hours	NNS	O
0	0	O
		
PULMICORT	NNP	O
FLEXHALER	NNP	O
(	(	O
budesonide	JJ	O
inhalation	NN	O
powder	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
twice	RB	O
daily	RB	O
by	IN	O
the	DT	O
orally	RB	O
inhaled	VBN	O
route	NN	O
only	RB	O
0	0	O
		
The	DT	O
usual	JJ	O
daily	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
PURINETHOL	NNP	O
is	VBZ	O
1.5	CD	DOS
to	TO	O
2.5	CD	DOS
mg/kg/day	NN	UNIT
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
0	0	O
		
Usual	JJ	O
dose	NN	O
:	:	O
Pyrazinamide	NNP	O
is	VBZ	O
administered	VBN	O
orally	RB	O
,	,	O
15	CD	DOS
to	TO	O
30	CD	DOS
mg/kg	NNS	UNIT
once	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
QBRELIS	NNP	O
,	,	O
when	WRB	O
used	VBN	O
with	IN	O
diuretics	NNS	O
and	CC	O
(	(	O
usually	RB	O
)	)	O
digitalis	NN	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
for	IN	O
systolic	JJ	O
heart	NN	O
failure	NN	O
,	,	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
adult	NN	O
dose	NN	O
for	IN	O
all	DT	O
QUESTRAN	NNP	O
powdered	VBN	O
products	NNS	O
(	(	O
QUESTRAN	NNP	O
Powder	NNP	O
and	CC	O
QUESTRAN	NNP	O
Light	NNP	O
)	)	O
is	VBZ	O
one	CD	DOS
packet	NN	UNIT
or	CC	O
one	CD	DOS
level	NN	UNIT
scoopful	JJ	UNIT
once	RB	O
or	CC	O
twice	VB	O
a	DT	O
day	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
QUILLIVANT	NNP	O
XR	NNP	O
for	IN	O
patients	NNS	O
6	CD	O
years	NNS	O
and	CC	O
above	NN	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
in	IN	O
the	DT	O
morning	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Qutenza	NNP	O
is	VBZ	O
a	DT	O
single	JJ	DOS
,	,	O
60-minute	JJ	O
application	NN	UNIT
of	IN	O
up	IN	O
to	TO	O
four	CD	O
patches	NNS	O
0	0	O
		
One	CD	DOS
RAGWITEK	NNP	O
tablet	NN	UNIT
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
8	CD	DOS
mg	NN	UNIT
orally	RB	O
once	RB	O
daily	JJ	O
with	IN	O
a	DT	O
meal	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
RAPIVAB	NNP	O
in	IN	O
adult	NN	O
patients	NNS	O
18	CD	O
years	NNS	O
of	IN	O
age	NN	O
or	CC	O
older	JJR	O
with	IN	O
acute	NN	O
uncomplicated	JJ	O
influenza	NN	O
is	VBZ	O
a	DT	O
single	JJ	DOS
600	CD	O
mg	NN	O
dose	NN	UNIT
,	,	O
administered	VBN	O
via	IN	O
intravenous	JJ	O
infusion	NN	O
for	IN	O
15	CD	O
to	TO	O
30	CD	O
minutes	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
REBIF	NNP	O
is	VBZ	O
either	RB	O
22	CD	DOS
mcg	NN	UNIT
or	CC	O
44	CD	DOS
mcg	NNS	UNIT
injected	VBD	O
subcutaneously	RB	O
three	CD	O
times	NNS	O
per	IN	O
week	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
regimen	NN	O
is	VBZ	O
a	DT	O
5	CD	DOS
mg	NN	UNIT
infusion	NN	O
once	RB	O
a	DT	O
year	NN	O
given	VBN	O
intravenously	RB	O
over	IN	O
no	DT	O
less	JJR	O
than	IN	O
15	CD	O
minutes	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
RELISTOR	NNP	O
is	VBZ	O
12	CD	DOS
mg	NN	UNIT
subcutaneously	RB	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
REMERON	NNP	O
(	(	O
mirtazapine	NN	O
)	)	O
Tablets	NNPS	O
is	VBZ	O
15	CD	DOS
mg/day	NN	UNIT
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
,	,	O
preferably	RB	O
in	IN	O
the	DT	O
evening	NN	O
prior	RB	O
to	TO	O
sleep	VB	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
REMERONSolTab??	NNP	O
(	(	O
mirtazapine	NN	O
)	)	O
Orally	RB	O
Disintegrating	VBG	O
Tablets	NNP	O
is	VBZ	O
15	CD	DOS
mg/day	NN	UNIT
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
,	,	O
preferably	RB	O
in	IN	O
the	DT	O
evening	NN	O
prior	RB	O
to	TO	O
sleep	VB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
REMICADE	NNP	O
is	VBZ	O
5	CD	DOS
mg/kg	NN	UNIT
given	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
induction	NN	O
regimen	NNS	O
at	IN	O
0	CD	O
,	,	O
2	CD	O
and	CC	O
6	CD	O
weeks	NNS	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
regimen	NN	O
of	IN	O
5	CD	DOS
mg/kg	NN	UNIT
every	DT	O
8	CD	O
weeks	NNS	O
thereafter	RB	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
adults	NNS	O
with	IN	O
moderately	RB	O
to	TO	O
severely	RB	O
active	JJ	O
Crohn	NNP	O
's	POS	O
disease	NN	O
or	CC	O
fistulizing	VBG	O
Crohn	NNP	O
's	POS	O
disease	NN	O
0	0	O
		
Based	VBN	O
on	IN	O
clinical	JJ	O
studies	NNS	O
,	,	O
the	DT	O
average	JJ	O
prescribed	JJ	O
adult	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
sevelamer	JJ	O
carbonate	NN	O
is	VBZ	O
approximately	RB	O
7.2	CD	DOS
g	NNS	UNIT
per	IN	O
day	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Abciximab	NNP	O
in	IN	O
adults	NNS	O
is	VBZ	O
a	DT	O
0.25	CD	DOS
mg/kg	NN	UNIT
intravenous	JJ	O
bolus	NN	O
administered	VBD	O
10-60	JJ	O
minutes	NNS	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
PCI	NNP	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
continuous	JJ	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
0.125	CD	DOS
??g/kg/min	NNS	UNIT
(	(	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
10	CD	DOS
??g/min	NNS	UNIT
)	)	O
for	IN	O
12	CD	O
hours	NNS	O
0	0	O
		
For	IN	O
the	DT	O
short-term	JJ	O
(	(	O
generally	RB	O
less	JJR	O
than	IN	O
10	CD	O
days	NNS	O
)	)	O
management	NN	O
of	IN	O
acute	NN	O
pain	NN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
REPREXAIN?"?	NNP	O
is	VBZ	O
one	CD	O
tablet	NN	O
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
,	,	O
as	IN	O
necessary	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
is	VBZ	O
0.25	CD	DOS
mg	NN	UNIT
three	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
twice	RB	O
daily	RB	O
0	0	O
		
RETIN-A	NNP	O
Gel	NNP	O
,	,	O
Cream	NNP	O
or	CC	O
Liquid	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
once	RB	O
a	DT	O
day	NN	O
,	,	O
before	IN	O
retiring	VBG	O
,	,	O
to	TO	O
the	DT	O
skin	NN	O
where	WRB	O
acne	NN	O
lesions	NNS	O
appear	VBP	O
,	,	O
using	VBG	O
enough	JJ	O
to	TO	O
cover	VB	O
the	DT	O
entire	JJ	O
affected	JJ	O
area	NN	O
lightly	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
RETROVIR	NNP	O
is	VBZ	O
300	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antiretroviral	JJ	O
agents	NNS	O
0	0	O
		
This	DT	O
dose	NN	O
should	MD	O
be	VB	O
administered	VBN	O
5	CD	O
to	TO	O
6	CD	O
times	NNS	O
daily	RB	O
(	(	O
5	CD	DOS
to	TO	O
6	CD	DOS
mg/kg	NNS	UNIT
daily	RB	O
)	)	O
0	0	O
		
The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
600	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
Methotrexate	NNP	O
is	VBZ	O
administered	VBN	O
orally	RB	O
or	CC	O
intramuscularly	RB	O
in	IN	O
doses	NNS	O
of	IN	O
15	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
daily	RB	O
for	IN	O
a	DT	O
five-day	JJ	O
course	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dosage	NN	O
of	IN	O
RIDAURA	NNP	O
(	(	O
auranofin	NN	O
)	)	O
is	VBZ	O
6	CD	DOS
mg	JJ	UNIT
daily	JJ	O
,	,	O
given	VBN	O
either	CC	O
as	IN	O
3	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
or	CC	O
6	CD	DOS
mg	NNS	UNIT
once	RB	O
daily	RB	O
0	0	O
		
RISPERDAL??	NNP	O
CONSTA??	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
every	DT	O
2	CD	O
weeks	NNS	O
by	IN	O
deep	JJ	O
intramuscular	NN	O
(	(	O
IM	NNP	O
)	)	O
deltoid	NN	O
or	CC	O
gluteal	JJ	O
injection	NN	O
0	0	O
		
A	DT	O
dose	NN	O
of	IN	O
1500	CD	DOS
international	JJ	UNIT
units	NNS	UNIT
of	IN	O
RIXUBIS	NNP	O
,	,	O
administered	VBD	O
to	TO	O
a	DT	O
20	CD	O
kg	NN	O
patient	NN	O
should	MD	O
be	VB	O
expect	VB	O
to	TO	O
result	VB	O
in	IN	O
a	DT	O
peak	JJ	O
post-infusion	NN	O
factor	NN	O
IX	NNP	O
increase	NN	O
of	IN	O
1500	CD	DOS
international	JJ	UNIT
units	NNS	UNIT
x	VBP	O
{	(	O
[	JJ	O
0.7	CD	DOS
IU/dL	NNP	UNIT
]	NNP	O
/	NNP	O
[	NNP	O
IU/kg	NNP	O
}	)	O
/	NNP	O
[	$	O
20	CD	O
kg	NN	O
]	NNP	O
=	VBZ	O
53.6	CD	DOS
international	JJ	UNIT
units/dL	NN	UNIT
(	(	O
53.6	CD	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
every	DT	O
6	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ROZEREM	NNP	O
(	(	O
ramelteon	NN	O
)	)	O
is	VBZ	O
8	CD	DOS
mg	NN	UNIT
taken	VBN	O
within	IN	O
30	CD	O
minutes	NNS	O
of	IN	O
going	VBG	O
to	TO	O
bed	VB	O
0	0	O
		
The	DT	O
recommended	JJ	O
starting	VBG	O
daily	JJ	O
dose	NN	O
of	IN	O
rufinamide	NN	O
in	IN	O
pediatric	JJ	O
patients	NNS	O
with	IN	O
Lennox-Gastaut	NNP	O
Syndrome	NNP	O
is	VBZ	O
approximately	RB	O
10	CD	DOS
mg/kg	NNS	UNIT
administered	VBN	O
in	IN	O
two	CD	O
equally	RB	O
divided	JJ	O
doses	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
prophylactic	JJ	O
dose	NN	O
of	IN	O
RYANODEX	NNP	O
is	VBZ	O
2.5	CD	DOS
mg/kg	NN	UNIT
administered	VBD	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
1	CD	O
minute	NN	O
,	,	O
starting	VBG	O
approximately	RB	O
75	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
surgery	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
RYTARY	NNP	O
in	IN	O
levodopa-na??ve	JJ	O
patients	NNS	O
is	VBZ	O
23.75	CD	DOS
mg	NN	UNIT
/	VBD	O
95	CD	DOS
mg	NN	UNIT
taken	VBN	O
orally	RB	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
for	IN	O
the	DT	O
first	JJ	O
3	CD	O
days	NNS	O
0	0	O
		
Take	VB	O
one	CD	DOS
tablet	NN	UNIT
by	IN	O
mouth	NN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
every	DT	O
day	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
20	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
SANCTURA	NNP	O
XR??	NNP	O
is	VBZ	O
one	CD	DOS
60	CD	O
mg	NN	O
capsule	NN	UNIT
daily	RB	O
in	IN	O
the	DT	O
morning	NN	O
0	0	O
		
The	DT	O
initial	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
Sandimmune	NNP	O
(	(	O
cyclosporine	NN	O
)	)	O
should	MD	O
be	VB	O
given	VBN	O
4	CD	O
to	TO	O
12	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
transplantation	NN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
15	CD	DOS
mg/kg	NN	UNIT
0	0	O
		
Usual	JJ	O
adult	NN	O
dose	JJ	O
4-8	JJ	DOS
mg	JJ	UNIT
daily	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
SAPHRIS	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
given	VBN	O
twice	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
SARAFEM	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
PMDD	NNP	O
is	VBZ	O
20	CD	DOS
mg/day	NN	UNIT
given	VBN	O
continuously	RB	O
(	(	O
every	DT	O
day	NN	O
of	IN	O
the	DT	O
menstrual	JJ	O
cycle	NN	O
)	)	O
or	CC	O
intermittently	RB	O
(	(	O
defined	VBN	O
as	IN	O
starting	VBG	O
a	DT	O
daily	JJ	O
dose	JJ	O
14	CD	O
days	NNS	O
prior	RB	O
to	TO	O
the	DT	O
anticipated	JJ	O
onset	NN	O
of	IN	O
menstruation	NN	O
through	IN	O
the	DT	O
first	JJ	O
full	JJ	O
day	NN	O
of	IN	O
menses	NNS	O
and	CC	O
repeating	VBG	O
with	IN	O
each	DT	O
new	JJ	O
cycle	NN	O
)	)	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
SAVAYSA	NNP	O
is	VBZ	O
60	CD	DOS
mg	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Savella	NNP	O
is	VBZ	O
100	CD	DOS
mg/day	NN	UNIT
(	(	O
50	CD	DOS
mg	NN	UNIT
twice	RB	O
daily	RB	O
)	)	O
0	0	O
		
Treatment	NN	O
of	IN	O
tinea	NN	O
versicolor	NN	O
:	:	O
Apply	VB	O
to	TO	O
affected	JJ	O
areas	NNS	O
and	CC	O
lather	NN	O
with	IN	O
a	DT	O
small	JJ	O
amount	NN	O
of	IN	O
water	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Silenor	NNP	O
(	(	O
doxepin	JJ	O
tablets	NNS	O
)	)	O
for	IN	O
adults	NNS	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
SIMCOR	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	O
dose	NN	UNIT
at	IN	O
bedtime	NN	O
,	,	O
with	IN	O
a	DT	O
low	JJ	O
fat	JJ	O
snack	NN	O
0	0	O
		
The	DT	O
SIMPONI	NNP	O
ARIA	NNP	O
dosage	NN	O
regimen	NNS	O
is	VBZ	O
2	CD	DOS
mg	NN	UNIT
per	IN	O
kg	NN	O
given	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
30	CD	O
minutes	NNS	O
at	IN	O
weeks	NNS	O
0	CD	O
and	CC	O
4	CD	O
,	,	O
then	RB	O
every	DT	O
8	CD	O
weeks	NNS	O
thereafter	RB	O
0	0	O
		
The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
5	CD	DOS
to	TO	O
40	CD	DOS
mg/day	NN	UNIT
0	0	O
		
One	CD	DOS
SITAVIG	NNP	O
50	CD	O
mg	NN	O
buccal	JJ	O
tablet	NN	UNIT
should	MD	O
be	VB	O
applied	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
to	TO	O
the	DT	O
upper	JJ	O
gum	NN	O
region	NN	O
(	(	O
canine	JJ	O
fossa	NN	O
)	)	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
SIVEXTRO	NNP	O
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
administered	VBN	O
once	RB	O
daily	JJ	O
for	IN	O
six	CD	O
(	(	O
6	CD	O
)	)	O
days	NNS	O
either	CC	O
orally	RB	O
(	(	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
)	)	O
or	CC	O
as	IN	O
an	DT	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
infusion	NN	O
in	IN	O
patients	NNS	O
18	CD	O
years	NNS	O
of	IN	O
age	NN	O
or	CC	O
older	JJR	O
0	0	O
		
Apply	VB	O
the	DT	O
entire	JJ	O
contents	NNS	O
of	IN	O
the	DT	O
84-gram	JJ	O
package	NN	O
of	IN	O
SERPACWA	NNP	O
evenly	RB	O
to	TO	O
the	DT	O
areas	NNS	O
of	IN	O
the	DT	O
skin	NN	O
(	(	O
as	IN	O
outlined	VBN	O
in	IN	O
Instructions	NNP	O
for	IN	O
Use	NNP	O
for	IN	O
Military	NNP	O
Personnel	NNP	O
below	IN	O
)	)	O
prior	RB	O
to	TO	O
donning	VBG	O
MOPP	NNP	O
gear	NN	O
0	0	O
		
Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
to	TO	O
affected	VBN	O
areas	NNS	O
with	IN	O
light	JJ	O
massaging	VBG	O
,	,	O
1	CD	O
to	TO	O
3	CD	O
times	NNS	O
daily	RB	O
,	,	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
SOLODYN	NNP	O
is	VBZ	O
approximately	RB	O
1	CD	DOS
mg/kg	NNS	UNIT
once	RB	O
daily	RB	O
for	IN	O
12	CD	O
weeks	NNS	O
0	0	O
		
The	DT	O
range	NN	O
of	IN	O
initial	JJ	O
doses	NNS	O
is	VBZ	O
0.11	CD	DOS
to	TO	O
1.6	CD	DOS
mg/kg/day	NN	UNIT
in	IN	O
three	CD	O
or	CC	O
four	CD	O
divided	VBN	O
doses	NNS	O
(	(	O
3.2	CD	DOS
to	TO	O
48	CD	DOS
mg/m??bsa/day	NN	UNIT
)	)	O
0	0	O
		
The	DT	O
recommended	JJ	O
loading	NN	O
dose	NN	O
of	IN	O
SOMAVERT	NNP	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
given	VBN	O
subcutaneously	RB	O
,	,	O
under	IN	O
healthcare	NN	O
provider	NN	O
supervision	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
80	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
0	0	O
		
The	DT	O
dosage	NN	O
should	MD	O
be	VB	O
kept	VBN	O
small	JJ	O
,	,	O
using	VBG	O
0.5	CD	DOS
to	TO	O
2	CD	DOS
mL	NN	UNIT
(	(	O
preferably	RB	O
1	CD	DOS
mL	NNS	UNIT
maximum	JJ	O
)	)	O
for	IN	O
each	DT	O
injection	NN	O
,	,	O
and	CC	O
the	DT	O
maximum	JJ	O
single	JJ	O
treatment	NN	O
should	MD	O
not	RB	O
exceed	VB	O
10	CD	O
mL	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Sotret	NNP	O
(	(	O
isotret	JJ	O
(	(	O
isotret	JJ	O
(	(	O
isotretinoin	JJ	O
capsules	NNS	O
)	)	O
inoin	VBP	O
capsules	NNS	O
)	)	O
inoin	VBP	O
capsules	NNS	O
)	)	O
is	VBZ	O
0.5	CD	DOS
to	TO	O
1	CD	DOS
mg/kg/day	NN	UNIT
given	VBN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
with	IN	O
food	NN	O
for	IN	O
15	CD	O
to	TO	O
20	CD	O
weeks	NNS	O
0	0	O
		
Apply	VB	O
a	DT	O
thin	JJ	O
layer	NN	O
(	(	O
1	CD	O
drop	NN	O
covers	VBZ	O
an	DT	O
area	NN	O
of	IN	O
skin	$	O
2	CD	O
inches	NNS	O
by	IN	O
2	CD	O
inches	NNS	O
)	)	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
3-4	JJ	O
times	NNS	O
over	IN	O
a	DT	O
24-hour	JJ	O
period	NN	O
,	,	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
,	,	O
and	CC	O
rub	NN	O
in	IN	O
gently	RB	O
0	0	O
		
To	TO	O
receive	VB	O
the	DT	O
full	JJ	O
dose	NN	O
of	IN	O
medication	NN	O
,	,	O
SPIRIVA	NNP	O
RESPIMAT	NNP	O
must	MD	O
be	VB	O
administered	VBN	O
as	IN	O
two	CD	DOS
inhalations	NNS	UNIT
once-daily	RB	O
0	0	O
		
The	DT	O
maximum	JJ	O
daily	JJ	O
dose	NN	O
is	VBZ	O
63	CD	DOS
mg	NN	UNIT
(	(	O
four	CD	DOS
doses	NNS	UNIT
)	)	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
SPRYCEL	NNP	O
for	IN	O
chronic	JJ	O
phase	NN	O
CML	NNP	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
administered	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
usual	JJ	O
recommended	VBD	O
dose	NN	O
for	IN	O
initial	JJ	O
nasal	JJ	O
administration	NN	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
(	(	O
1	CD	DOS
spray	NN	UNIT
in	IN	O
one	CD	O
nostril	NN	O
)	)	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
750	CD	DOS
mg	JJ	UNIT
daily	RB	O
in	IN	O
divided	JJ	O
doses	NNS	O
0	0	O
		
The	DT	O
maximum	JJ	O
dosing	NN	O
frequency	NN	O
is	VBZ	O
one	CD	DOS
STAXYN	NNP	O
tablet	NN	UNIT
per	IN	O
day	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
Striant	NNP	O
is	VBZ	O
the	DT	O
application	NN	O
of	IN	O
one	CD	DOS
buccal	JJ	UNIT
system	NN	UNIT
(	(	O
30	CD	DOS
mg	NN	UNIT
)	)	O
to	TO	O
the	DT	O
gum	JJ	O
region	NN	O
twice	RB	O
daily	RB	O
;	:	O
morning	NN	O
and	CC	O
evening	NN	O
(	(	O
about	IN	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
0	0	O
		
The	DT	O
maximum	JJ	O
single	JJ	O
recommended	VBD	O
dose	NN	O
of	IN	O
Sumavel	NNP	O
DosePro	NNP	O
for	IN	O
the	DT	O
acute	JJ	O
treatment	NN	O
of	IN	O
migraine	NN	O
or	CC	O
cluster	NN	O
headache	NN	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
given	VBN	O
subcutaneously	RB	O
0	0	O
		
SYLVANT	NNP	O
11	CD	DOS
mg/kg	NN	UNIT
is	VBZ	O
given	VBN	O
over	IN	O
1	CD	O
hour	NN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
administered	VBD	O
every	DT	O
3	CD	O
weeks	NNS	O
until	IN	O
treatment	NN	O
failure	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dose	NN	O
is	VBZ	O
two	CD	DOS
capsules	NNS	UNIT
every	DT	O
4	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
complicated	VBN	O
skin	NN	O
and	CC	O
skin	NN	O
structure	NN	O
infections	NNS	O
is	VBZ	O
7.5	CD	DOS
mg/kg	NN	UNIT
q12h	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
starting	NN	O
schedule	NN	O
for	IN	O
induction	NN	O
is	VBZ	O
1.25	CD	DOS
mg/m??administered	JJ	UNIT
subcutaneously	RB	O
twice	JJ	O
daily	RB	O
for	IN	O
14	CD	O
consecutive	JJ	O
days	NNS	O
every	DT	O
28	CD	O
days	NNS	O
,	,	O
over	IN	O
a	DT	O
28-day	JJ	O
cycle	NN	O
0	0	O
		
However	RB	O
,	,	O
on	IN	O
limited	JJ	O
clinical	JJ	O
experience	NN	O
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
SYPRINE	NNP	O
is	VBZ	O
500-750	JJ	DOS
mg/day	NN	UNIT
for	IN	O
pediatric	JJ	O
patients	NNS	O
and	CC	O
750-1250	JJ	DOS
mg/day	NN	UNIT
for	IN	O
adults	NNS	O
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
two	CD	O
,	,	O
three	CD	O
or	CC	O
four	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
160	CD	DOS
mg	NN	UNIT
(	(	O
two	CD	O
80	CD	DOS
mg	NNS	UNIT
injections	NNS	O
)	)	O
at	IN	O
Week	NNP	O
0	CD	O
,	,	O
followed	VBN	O
by	IN	O
80	CD	DOS
mg	NNS	UNIT
at	IN	O
Weeks	NNP	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
8	CD	O
,	,	O
10	CD	O
,	,	O
and	CC	O
12	CD	O
,	,	O
then	RB	O
80	CD	DOS
mg	NNS	UNIT
every	DT	O
4	CD	O
weeks	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dose	NN	O
is	VBZ	O
2	CD	DOS
caplets	NNS	UNIT
three	CD	O
or	CC	O
four	CD	O
times	NNS	O
a	DT	O
day	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
Targretin??	NNP	O
(	(	O
bexarotene	NN	O
)	)	O
capsules	VBZ	O
is	VBZ	O
300	CD	DOS
mg/m2/day	NN	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TECENTRIQ	NNP	O
is	VBZ	O
1200	CD	DOS
mg	NN	UNIT
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
60	CD	O
minutes	NNS	O
every	DT	O
3	CD	O
weeks	NNS	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
unacceptable	JJ	O
toxicity	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Teflaro	NNP	O
is	VBZ	O
600	CD	DOS
mg	NN	UNIT
administered	VBN	O
every	DT	O
12	CD	O
hours	NNS	O
by	IN	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
infusion	NN	O
over	IN	O
5	CD	O
to	TO	O
60	CD	O
minutes	NNS	O
in	IN	O
patients	NNS	O
???	JJ	O
18	CD	O
years	NNS	O
of	IN	O
age	NN	O
0	0	O
		
Chlorthalidone	NN	O
is	VBZ	O
usually	RB	O
given	VBN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
25	CD	DOS
mg	JJ	UNIT
daily	RB	O
;	:	O
the	DT	O
usual	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
atenolol	NN	O
is	VBZ	O
50	CD	DOS
mg	JJ	UNIT
daily	RB	O
0	0	O
		
Adults	NNS	O
:	:	O
The	DT	O
usual	JJ	O
daily	JJ	O
dose	NN	O
is	VBZ	O
250	CD	DOS
mg	NN	UNIT
administered	VBN	O
once	RB	O
every	DT	O
24	CD	O
hours	NNS	O
or	CC	O
300	CD	DOS
mg	NNS	UNIT
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
at	IN	O
8	CD	O
to	TO	O
12	CD	O
hour	NN	O
intervals	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
for	IN	O
adult	NN	O
schizophrenic	JJ	O
patients	NNS	O
is	VBZ	O
50	CD	DOS
to	TO	O
100	CD	DOS
mg	NNS	UNIT
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
,	,	O
with	IN	O
a	DT	O
gradual	JJ	O
increment	NN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
800	CD	O
mg	NNS	O
daily	RB	O
if	IN	O
necessary	JJ	O
0	0	O
		
Adults	NNS	O
:	:	O
The	DT	O
usual	JJ	O
recommended	JJ	O
dosage	NN	O
for	IN	O
systemic	JJ	O
and	CC	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
for	IN	O
average	NN	O
(	(	O
60	CD	O
kg	NN	O
)	)	O
adults	NNS	O
is	VBZ	O
3.1	CD	DOS
grams	NNS	UNIT
of	IN	O
TIMENTIN	NNP	O
(	(	O
3.1-gram	JJ	O
vial	NN	O
containing	VBG	O
3	CD	O
grams	NNS	O
ticarcillin	NN	O
and	CC	O
100	CD	O
mg	NN	O
clavulanic	JJ	O
acid	NN	O
)	)	O
given	VBN	O
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
recommended	JJ	O
dosage	NN	O
for	IN	O
systemic	JJ	O
and	CC	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
for	IN	O
adults	NNS	O
is	VBZ	O
3.1	CD	DOS
grams	NNS	UNIT
of	IN	O
TIMENTIN	NNP	O
(	(	O
3	CD	O
grams	NNS	O
ticarcillin	NN	O
and	CC	O
100	CD	O
mg	NN	O
clavulanic	JJ	O
acid	NN	O
)	)	O
given	VBN	O
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
0.25	CD	O
%	NN	O
TIMOPTIC	NNP	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
twice	RB	O
a	DT	O
day	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
0.25	CD	O
percent	JJ	O
Preservative-free	JJ	O
TIMOPTIC	NNP	O
in	IN	O
OCUDOSE	NNP	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
administered	VBD	O
twice	RB	O
a	DT	O
day	NN	O
0	0	O
		
The	DT	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
TIMOPTIC-XE	NNP	O
(	(	O
either	CC	O
0.25	CD	O
%	NN	O
or	CC	O
0.5	CD	O
%	NN	O
)	)	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
once	RB	O
a	DT	O
day	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
both	DT	O
adults	NNS	O
and	CC	O
pediatric	JJ	O
patients	NNS	O
6	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
older	JJR	O
is	VBZ	O
1	CD	DOS
single-use	NN	O
ampule	NN	UNIT
(	(	O
300	CD	DOS
mg	NN	UNIT
)	)	O
administered	VBD	O
BID	NNP	O
for	IN	O
28	CD	O
days	NNS	O
0	0	O
		
TOBI	NNP	O
Podhaler	NNP	O
is	VBZ	O
administered	VBN	O
twice-daily	RB	O
in	IN	O
alternating	VBG	O
periods	NNS	O
of	IN	O
28	CD	O
days	NNS	O
0	0	O
		
One	CD	DOS
or	CC	O
two	CD	DOS
drops	NNS	UNIT
instilled	VBD	O
into	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
(	(	O
s	PRP	O
)	)	O
every	DT	O
four	CD	O
to	TO	O
six	CD	O
hours	NNS	O
0	0	O
		
Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
into	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
(	(	O
s	PRP	O
)	)	O
every	DT	O
four	CD	O
to	TO	O
six	CD	O
hours	NNS	O
0	0	O
		
Apply	NNP	O
Tolak	NNP	O
Cream	NNP	O
once	RB	O
daily	RB	O
in	IN	O
an	DT	O
amount	NN	O
sufficient	NN	O
to	TO	O
cover	VB	O
the	DT	O
lesions	NNS	O
of	IN	O
the	DT	O
face	NN	O
,	,	O
ears	NNS	O
,	,	O
and/or	JJ	O
scalp	NN	O
with	IN	O
a	DT	O
thin	JJ	O
film	NN	O
,	,	O
using	VBG	O
the	DT	O
fingertips	NNS	O
to	TO	O
gently	RB	O
massage	VB	O
the	DT	O
medication	NN	O
uniformly	RB	O
into	IN	O
the	DT	O
skin	NN	O
0	0	O
		
For	IN	O
the	DT	O
relief	NN	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
or	CC	O
osteoarthritis	NN	O
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
adults	NNS	O
is	VBZ	O
400	CD	DOS
mg	NN	UNIT
three	CD	O
times	NNS	O
daily	RB	O
(	(	O
1200	CD	DOS
mg	FW	UNIT
daily	RB	O
)	)	O
,	,	O
preferably	RB	O
including	VBG	O
a	DT	O
dose	NN	O
on	IN	O
arising	VBG	O
and	CC	O
a	DT	O
dose	NN	O
at	IN	O
bedtime	NN	O
0	0	O
		
Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Topicort??	NNP	O
(	(	O
desoximetasone	NN	O
)	)	O
Ointment	NNP	O
USP	NNP	O
,	,	O
0.05	CD	O
%	NN	O
to	TO	O
the	DT	O
affected	JJ	O
skin	NN	O
areas	NNS	O
twice	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TORISEL	NNP	O
for	IN	O
advanced	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
infused	VBN	O
over	IN	O
a	DT	O
30	CD	O
??"	NN	O
60	CD	O
minute	NN	O
period	NN	O
once	IN	O
a	DT	O
week	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TRADJENTA	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
The	DT	O
suggested	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
between	IN	O
0.2	CD	DOS
mg/hr*	NN	UNIT
,	,	O
and	CC	O
0.4	CD	DOS
mg/hr*	NN	UNIT
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
once	RB	O
daily	JJ	O
in	IN	O
the	DT	O
evening	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
Trental	NNP	O
(	(	O
pentoxifylline	NN	O
)	)	O
is	VBZ	O
400	CD	DOS
mg	JJ	UNIT
twice	RB	O
daily	RB	O
after	IN	O
meals	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dosage	NN	O
is	VBZ	O
two	CD	DOS
(	(	O
2	CD	O
)	)	O
TREZIX?"?	NNP	O
capsules	NNS	UNIT
orally	RB	O
every	DT	O
four	CD	O
(	(	O
4	CD	O
)	)	O
hours	NNS	O
,	,	O
as	IN	O
needed	VBN	O
0	0	O
		
0.9-2.4	JJ	DOS
grams	NNS	UNIT
daily	RB	O
in	IN	O
3	CD	O
or	CC	O
4	CD	O
equally	RB	O
divided	VBN	O
doses	NNS	O
(	(	O
i.e.	JJ	O
,	,	O
300-600	JJ	DOS
mg	NN	UNIT
3	CD	O
or	CC	O
4	CD	O
times	NNS	O
daily	RB	O
)	)	O
0	0	O
		
The	DT	O
dosage	NN	O
regimen	NNS	O
for	IN	O
TriNessa??	NNP	O
for	IN	O
treatment	NN	O
of	IN	O
facial	JJ	O
acne	NN	O
,	,	O
as	IN	O
available	JJ	O
in	IN	O
a	DT	O
blister	NN	O
card	NN	O
with	IN	O
a	DT	O
tablet	NN	O
dispenser	NN	O
,	,	O
utilizes	VBZ	O
a	DT	O
21-day	JJ	O
active	JJ	O
and	CC	O
a	DT	O
7-day	JJ	O
placebo	NN	O
schedule	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
TrophAmine	NNP	O
is	VBZ	O
2	CD	DOS
to	TO	O
2.5	CD	DOS
grams	NNS	UNIT
of	IN	O
amino	JJ	O
acids	NNS	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	O
day	NN	O
(	(	O
2	CD	DOS
to	TO	O
2.5	CD	DOS
g/kg/day	NN	UNIT
)	)	O
for	IN	O
infants	NNS	O
up	RB	O
to	TO	O
10	CD	O
kilograms	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
regimen	NN	O
is	VBZ	O
a	DT	O
single	JJ	DOS
100-mg	JJ	DOS
tablet	NN	UNIT
of	IN	O
TROVAN	NNP	O
and	CC	O
a	DT	O
single	JJ	DOS
1-gram	CD	DOS
(	(	O
1000	CD	DOS
mg	NN	UNIT
)	)	O
dose	NN	UNIT
of	IN	O
ZITHROMAX	NNP	O
for	IN	O
oral	JJ	O
suspension	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
initiating	NN	O
dose	NN	O
of	IN	O
TRULICITY	NNP	O
is	VBZ	O
0.75	CD	DOS
mg	NN	UNIT
once	RB	O
weekly	JJ	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
regimen	NNS	O
for	IN	O
TYGACIL	NNP	O
is	VBZ	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
100	CD	DOS
mg	NN	UNIT
,	,	O
followed	VBN	O
by	IN	O
50	CD	DOS
mg	NNS	UNIT
every	DT	O
12	CD	O
hours	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TYKERB	NNP	O
is	VBZ	O
1250	CD	DOS
mg	NN	UNIT
given	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
on	IN	O
Days	NNP	O
1-21	CD	O
continuously	RB	O
in	IN	O
combination	NN	O
with	IN	O
capecitabine	JJ	O
2000	CD	O
mg/m??/day	NN	O
(	(	O
administered	VBN	O
orally	RB	O
in	IN	O
2	CD	O
doses	NNS	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
on	IN	O
Days	NNP	O
1-14	NN	O
in	IN	O
a	DT	O
repeating	JJ	O
21-day	JJ	O
cycle	NN	O
0	0	O
		
The	DT	O
maximum	NN	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
9	CD	DOS
breaths	NNS	UNIT
per	IN	O
treatment	NN	O
session	NN	O
,	,	O
4	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Tyzeka	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
is	VBZ	O
600	CD	DOS
mg	NN	UNIT
once	RB	O
daily	JJ	O
,	,	O
taken	VBN	O
orally	RB	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
0	0	O
		
For	IN	O
patients	NNS	O
with	IN	O
moderate	JJ	O
to	TO	O
moderately	RB	O
severe	JJ	O
chronic	NN	O
pain	NN	O
not	RB	O
requiring	VBG	O
rapid	JJ	O
onset	NN	O
of	IN	O
analgesic	JJ	O
effect	NN	O
,	,	O
the	DT	O
tolerability	NN	O
of	IN	O
ULTRAM??	NNP	O
can	MD	O
be	VB	O
improved	VBN	O
by	IN	O
initiating	VBG	O
therapy	NN	O
with	IN	O
the	DT	O
following	JJ	O
titration	NN	O
regimen	NNS	O
:	:	O
ULTRAM??	NNP	O
should	MD	O
be	VB	O
started	VBN	O
at	IN	O
25	CD	DOS
mg/day	NN	UNIT
(	(	O
half	JJ	O
ULTRAM??	NNP	O
scored	VBD	O
tablet	NN	O
)	)	O
qAM	NN	O
and	CC	O
titrated	VBN	O
in	IN	O
25	CD	O
mg	NN	O
increments	NNS	O
as	IN	O
separate	JJ	O
doses	NNS	O
every	DT	O
3	CD	O
days	NNS	O
to	TO	O
reach	VB	O
100	CD	O
mg/day	NN	O
(	(	O
25	CD	O
mg	NN	O
q.i.d	NN	O
0	0	O
		
)	)	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
univasc??	JJ	O
in	IN	O
patients	NNS	O
not	RB	O
receiving	VBG	O
diuretics	NNS	O
is	VBZ	O
7.5	CD	DOS
mg	NN	UNIT
,	,	O
one	CD	O
hour	NN	O
prior	RB	O
to	TO	O
meals	NNS	O
,	,	O
once	RB	O
daily	JJ	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
UPTRAVI	NNP	O
is	VBZ	O
200	CD	DOS
micrograms	NNS	UNIT
(	(	O
mcg	NN	O
)	)	O
given	VBN	O
twice	JJ	O
daily	RB	O
0	0	O
		
A	DT	O
dose	NN	O
of	IN	O
1	CD	DOS
capsule	NN	UNIT
four	CD	O
times	NNS	O
daily	RB	O
is	VBZ	O
suggested	VBN	O
0	0	O
		
Patients	NNS	O
who	WP	O
are	VBP	O
opioid	JJ	O
tolerant	NN	O
are	VBP	O
those	DT	O
receiving	VBG	O
,	,	O
for	IN	O
one	CD	O
week	NN	O
or	CC	O
longer	JJR	O
,	,	O
at	IN	O
least	JJS	O
60	CD	DOS
mg	JJ	UNIT
oral	JJ	O
morphine	NN	O
per	IN	O
day	NN	O
,	,	O
25	CD	DOS
mcg	NN	UNIT
transdermal	JJ	O
fentanyl	NN	O
per	IN	O
hour	NN	O
,	,	O
30	CD	DOS
mg	JJ	UNIT
oral	JJ	O
oxycodone	NN	O
per	IN	O
day	NN	O
,	,	O
8	CD	DOS
mg	JJ	UNIT
oral	JJ	O
hydromorphone	NN	O
per	IN	O
day	NN	O
,	,	O
25	CD	DOS
mg	JJ	UNIT
oral	JJ	O
oxymorphone	NN	O
per	IN	O
day	NN	O
,	,	O
60	CD	DOS
mg	JJ	UNIT
oral	JJ	O
hydrocodone	NN	O
per	IN	O
day	NN	O
,	,	O
or	CC	O
an	DT	O
equianalgesic	JJ	O
dose	NN	O
of	IN	O
another	DT	O
opioid	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
of	IN	O
enalapril	NN	O
is	VBZ	O
10	CD	DOS
to	TO	O
40	CD	DOS
mg	NNS	UNIT
per	IN	O
day	NN	O
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
or	CC	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
0	0	O
		
The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
10	CD	DOS
to	TO	O
40	CD	DOS
mg	NNS	UNIT
per	IN	O
day	NN	O
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
or	CC	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
0	0	O
		
Usual	JJ	O
dose	NN	O
is	VBZ	O
2	CD	DOS
capsules	NNS	UNIT
daily	RB	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
0	0	O
		
Usual	JJ	O
dose	NN	O
is	VBZ	O
2	CD	DOS
capsules	NNS	UNIT
daily	RB	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Vectibix	NNP	O
is	VBZ	O
6	CD	DOS
mg/kg	NN	UNIT
,	,	O
administered	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
60	CD	O
minutes	NNS	O
,	,	O
every	DT	O
14	CD	O
days	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
VEMLIDY	NNP	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
(	(	O
one	CD	DOS
tablet	NN	UNIT
)	)	O
taken	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
with	IN	O
food	NN	O
0	0	O
		
The	DT	O
starting	NN	O
dose	NN	O
is	VBZ	O
12.5	CD	DOS
mg	NN	UNIT
once	RB	O
daily	JJ	O
or	CC	O
twice	JJ	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
VESIcare	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
Apply	VB	O
one	CD	DOS
-	:	DOS
two	CD	DOS
drops	NNS	UNIT
of	IN	O
VEXOL??	NNP	O
1	CD	O
%	NN	O
Ophthalmic	NNP	O
Suspension	NNP	O
into	IN	O
the	DT	O
conjunctival	JJ	O
sac	NN	O
of	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
four	CD	O
times	NNS	O
daily	RB	O
beginning	VBG	O
24	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
and	CC	O
continuing	VBG	O
throughout	IN	O
the	DT	O
first	JJ	O
2	CD	O
weeks	NNS	O
of	IN	O
the	DT	O
postoperative	JJ	O
period	NN	O
0	0	O
		
VICODIN??	NNP	O
(	(	O
Hydrocodone	NNP	O
Bitartrate	NNP	O
and	CC	O
Acetaminophen	NNP	O
Tablets	NNP	O
,	,	O
USP	NNP	O
5	CD	O
mg/300	NN	O
mg	NN	O
)	)	O
:	:	O
The	DT	O
usual	JJ	O
adult	NN	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
every	DT	O
four	CD	O
to	TO	O
six	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
0	0	O
		
Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
3	CD	O
times	NNS	O
a	DT	O
day	NN	O
for	IN	O
7	CD	O
days	NNS	O
0	0	O
		
The	DT	O
recommended	JJ	O
target	NN	O
dosage	NN	O
for	IN	O
VIIBRYD	NNP	O
is	VBZ	O
20	CD	DOS
mg	NN	UNIT
to	TO	O
40	CD	DOS
mg	NNS	UNIT
orally	RB	O
once	RB	O
daily	JJ	O
with	IN	O
food	NN	O
0	0	O
		
The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
VINCASAR	NNP	O
PFS	NNP	O
for	IN	O
adults	NNS	O
is	VBZ	O
1.4	CD	DOS
mg/m??	NN	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
1250	CD	DOS
mg	NN	UNIT
(	(	O
five	CD	DOS
250	CD	O
mg	NN	O
tablets	NNS	UNIT
or	CC	O
two	CD	DOS
625	CD	DOS
mg	NNS	O
tablets	NNS	UNIT
)	)	O
twice	RB	O
daily	RB	O
or	CC	O
750	CD	DOS
mg	NN	UNIT
(	(	O
three	CD	DOS
250	CD	O
mg	JJ	O
tablets	NNS	UNIT
)	)	O
three	CD	O
times	NNS	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	JJ	O
treatment	NN	O
regimen	NNS	O
is	VBZ	O
20	CD	DOS
mg/mL	JJ	UNIT
VIRAZOLE	NNP	O
(	(	O
ribavirin	NN	O
)	)	O
as	IN	O
the	DT	O
starting	VBG	O
solution	NN	O
in	IN	O
the	DT	O
drug	NN	O
reservoir	NN	O
of	IN	O
the	DT	O
SPAG-2	NNP	O
unit	NN	O
,	,	O
with	IN	O
continuous	JJ	O
aerosol	NNS	O
administration	NN	O
for	IN	O
12-18	JJ	O
hours	NNS	O
per	IN	O
day	NN	O
for	IN	O
3	CD	O
to	TO	O
7	CD	O
days	NNS	O
0	0	O
		
For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
HIV-1	NNP	O
or	CC	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
:	:	O
The	DT	O
dose	NN	O
is	VBZ	O
one	CD	DOS
300	CD	O
mg	NN	O
VIREAD	NNP	O
tablet	NN	UNIT
once	RB	O
daily	RB	O
taken	VBN	O
orally	RB	O
,	,	O
without	IN	O
regard	NN	O
to	TO	O
food	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
VIVITROL	NNP	O
is	VBZ	O
380	CD	DOS
mg	NN	UNIT
delivered	VBD	O
intramuscularly	RB	O
every	DT	O
4	CD	O
weeks	NNS	O
or	CC	O
once	RB	O
a	DT	O
month	NN	O
0	0	O
		
The	DT	O
maximum	NN	O
recommended	VBD	O
daily	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
VIVLODEX	NNP	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
0	0	O
		
One	CD	DOS
capsule	NN	UNIT
is	VBZ	O
to	TO	O
be	VB	O
swallowed	VBN	O
approximately	RB	O
1	CD	O
hour	NN	O
before	IN	O
a	DT	O
meal	NN	O
with	IN	O
a	DT	O
cold	JJ	O
or	CC	O
luke-warm	JJ	O
[	JJ	O
temperature	NN	O
not	RB	O
to	TO	O
exceed	VB	O
body	NN	O
temperature	NN	O
,	,	O
e.g.	NN	O
,	,	O
37	CD	O
??C	NN	O
(	(	O
98.6	CD	O
??F	NN	O
)	)	O
]	VBZ	O
drink	VBP	O
on	IN	O
alternate	NN	O
days	NNS	O
,	,	O
e.g.	NN	O
,	,	O
days	NNS	O
1	CD	O
,	,	O
3	CD	O
,	,	O
5	CD	O
and	CC	O
7	CD	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
Vizamyl	NNP	O
is	VBZ	O
185	CD	DOS
megabecquerels	NNS	UNIT
(	(	O
MBq	NNP	O
)	)	O
[	VBD	O
5	CD	DOS
millicuries	NNS	UNIT
(	(	O
mCi	NN	O
)	)	O
]	NN	O
in	IN	O
a	DT	O
maximum	JJ	O
dose	JJ	O
volume	NN	O
of	IN	O
10	CD	O
mL	NNS	O
,	,	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
intravenous	JJ	UNIT
bolus	NN	UNIT
within	IN	O
40	CD	O
seconds	NNS	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
VPRIV	NNP	O
dosage	NN	O
in	IN	O
na??ve	JJ	O
adults	NNS	O
and	CC	O
na??ve	JJ	O
pediatric	JJ	O
patients	NNS	O
4	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
older	JJR	O
is	VBZ	O
60	CD	DOS
Units/kg	NNP	UNIT
administered	VBN	O
every	DT	O
other	JJ	O
week	NN	O
as	IN	O
a	DT	O
60-minute	JJ	O
intravenous	JJ	O
infusion	NN	O
0	0	O
		
In	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
kidney	NN	O
disease	NN	O
and	CC	O
estimated	VBN	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
less	JJR	O
than	IN	O
60	CD	O
mL/min/1.73	JJ	O
m??	NN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
VYTORIN	NNP	O
is	VBZ	O
10/20	CD	DOS
mg/day	NN	UNIT
in	IN	O
the	DT	O
evening	NN	O
0	0	O
		
WESTCORT	NNP	O
CREAM	NNP	O
(	(	O
hydrocortisone	NN	O
valerate	NN	O
cream	NN	O
)	)	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
as	IN	O
a	DT	O
thin	JJ	O
film	NN	O
two	CD	O
or	CC	O
three	CD	O
times	NNS	O
daily	RB	O
depending	VBG	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
0	0	O
		
An	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
250	CD	DOS
international	JJ	UNIT
unit/kg	NN	O
(	(	O
50	CD	DOS
mcg/kg	NN	UNIT
)	)	O
body	NN	O
weight	NN	O
,	,	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
injection	NN	UNIT
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
ITP	NNP	O
0	0	O
		
The	DT	O
suggested	JJ	O
total	JJ	O
daily	JJ	O
dose	NN	O
ranges	VBZ	O
between	IN	O
3	CD	DOS
to	TO	O
6	CD	DOS
mg/day	NN	UNIT
0	0	O
		
The	DT	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
12.5	CD	DOS
mg	JJ	UNIT
per	IN	O
day	NN	O
given	VBN	O
once	RB	O
in	IN	O
the	DT	O
morning	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
XIFAXAN	NNP	O
is	VBZ	O
one	CD	DOS
200	CD	O
mg	NN	O
tablet	NN	UNIT
taken	VBN	O
orally	RB	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
for	IN	O
3	CD	O
days	NNS	O
0	0	O
		
Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
Xiidra	NNP	O
twice	RB	O
daily	RB	O
(	(	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
)	)	O
into	IN	O
each	DT	O
eye	NN	O
using	VBG	O
a	DT	O
single-use	JJ	O
container	NN	O
0	0	O
		
XTAMPZA	NN	O
ER	NNP	O
is	VBZ	O
administered	VBN	O
,	,	O
twice	RB	O
daily	RB	O
,	,	O
every	DT	O
12	CD	O
hours	NNS	O
,	,	O
and	CC	O
must	MD	O
be	VB	O
taken	VBN	O
with	IN	O
food	NN	O
0	0	O
		
Instill	NNP	O
four	CD	DOS
drops	NNS	UNIT
into	IN	O
the	DT	O
affected	JJ	O
ear	NN	O
(	(	O
s	PRP	O
)	)	O
twice	RB	O
daily	RB	O
for	IN	O
seven	CD	O
days	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablespoonful	NN	UNIT
(	(	O
15	CD	DOS
mL	NN	UNIT
)	)	O
every	DT	O
four	CD	O
to	TO	O
six	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
for	IN	O
weekly	JJ	O
intravenous	JJ	O
administration	NN	O
is	VBZ	O
1000	CD	DOS
mg/m??	NN	UNIT
of	IN	O
body	NN	O
surface	JJ	O
area	NN	O
at	IN	O
weekly	JJ	O
intervals	NNS	O
for	IN	O
the	DT	O
first	JJ	O
two	CD	O
courses	NNS	O
(	(	O
weeks	NNS	O
)	)	O
0	0	O
		
The	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	O
daily	RB	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ZELBORAF	NNP	O
is	VBZ	O
960	CD	DOS
mg	NN	UNIT
(	(	O
four	CD	DOS
240	CD	O
mg	NNS	O
tablets	NNS	UNIT
)	)	O
orally	RB	O
every	DT	O
12	CD	O
hours	NNS	O
with	IN	O
or	CC	O
without	IN	O
a	DT	O
meal	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
for	IN	O
Zenatane	NNP	O
is	VBZ	O
0.5	CD	DOS
to	TO	O
1	CD	DOS
mg/kg/day	NN	UNIT
given	VBN	O
in	IN	O
two	CD	O
divided	JJ	O
doses	NNS	O
with	IN	O
food	NN	O
for	IN	O
15	CD	O
to	TO	O
20	CD	O
weeks	NNS	O
0	0	O
		
Usual	JJ	O
dose	NN	O
is	VBZ	O
5	CD	DOS
to	TO	O
60	CD	DOS
mg	NNS	UNIT
per	IN	O
day	NN	O
in	IN	O
divided	JJ	O
doses	NNS	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
response	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ZEPATIER	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	O
daily	JJ	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
in	IN	O
adult	NN	O
patients	NNS	O
with	IN	O
hypertension	NN	O
taking	VBG	O
diuretics	NNS	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	O
per	IN	O
day	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
adult	NN	O
oral	JJ	O
dosage	NN	O
of	IN	O
ZOFRAN	NNP	O
is	VBZ	O
24	CD	DOS
mg	NN	UNIT
given	VBN	O
as	IN	O
three	CD	O
8-mg	JJ	O
tablets	NNS	O
administered	VBD	O
30	CD	O
minutes	NNS	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
single-day	JJ	O
highly	RB	O
emetogenic	JJ	O
chemotherapy	NN	O
,	,	O
including	VBG	O
cisplatin	NN	O
???	VBD	O
50	CD	DOS
mg/m	NN	UNIT
0	0	O
		
The	DT	O
recommended	VBN	O
adult	NN	O
intravenous	JJ	O
dosage	NN	O
of	IN	O
ZOFRAN	NNP	O
is	VBZ	O
three	CD	DOS
0.15-mg/kg	NN	O
doses	VBZ	UNIT
up	RP	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
16	CD	DOS
mg	NNS	UNIT
per	IN	O
dose	NN	O
0	0	O
		
Daily	JJ	O
doses	NNS	O
of	IN	O
ZOHYDRO	NNP	O
ER	NNP	O
,	,	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
greater	JJR	O
than	IN	O
40	CD	DOS
mg	NN	UNIT
,	,	O
or	CC	O
a	DT	O
total	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
greater	JJR	O
than	IN	O
80	CD	DOS
mg	NN	UNIT
,	,	O
are	VBP	O
only	RB	O
for	IN	O
use	NN	O
in	IN	O
patients	NNS	O
in	IN	O
whom	WP	O
tolerance	NN	O
to	TO	O
an	DT	O
opioid	NN	O
of	IN	O
comparable	JJ	O
potency	NN	O
has	VBZ	O
been	VBN	O
established	VBN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
400	CD	DOS
mg	NN	UNIT
orally	RB	O
once	RB	O
daily	JJ	O
with	IN	O
food	NN	O
0	0	O
		
A	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Zonalon	NNP	O
(	(	O
doxepin	NN	O
)	)	O
Cream	NN	O
should	MD	O
be	VB	O
applied	VBN	O
four	CD	O
times	NNS	O
each	DT	O
day	NN	O
with	IN	O
at	IN	O
least	JJS	O
a	DT	O
3	CD	O
to	TO	O
4	CD	O
hour	NN	O
interval	NN	O
between	IN	O
applications	NNS	O
0	0	O
		
The	DT	O
usual	JJ	O
total	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
ZOSYN	NNP	O
for	IN	O
adults	NNS	O
is	VBZ	O
3.375	CD	DOS
g	NN	UNIT
every	DT	O
six	CD	O
hours	NNS	O
totaling	VBG	O
13.5	CD	O
g	NN	O
(	(	O
12	CD	O
g	NN	O
piperacillin/1.5	NN	O
g	NN	O
tazobactam	NN	O
)	)	O
0	0	O
		
5	CD	DOS
mg/400	JJ	UNIT
mg	NN	O
:	:	O
The	DT	O
usual	JJ	O
adult	NN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
every	DT	O
four	CD	O
to	TO	O
six	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
0	0	O
		
The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ZYFLO	NNP	O
CR	NNP	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	O
with	IN	O
asthma	NN	O
is	VBZ	O
two	CD	DOS
600	CD	O
mg	NNS	O
extended-release	JJ	O
tablets	NNS	UNIT
twice	RB	O
daily	RB	O
,	,	O
within	IN	O
one	CD	O
hour	NN	O
after	IN	O
morning	NN	O
and	CC	O
evening	NN	O
meals	NNS	O
,	,	O
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	O
dose	NN	O
of	IN	O
2400	CD	DOS
mg.	JJ	UNIT
Tablets	NNS	O
should	MD	O
not	RB	O
be	VB	O
chewed	VBN	O
,	,	O
cut	VBD	O
or	CC	O
crushed	VBN	O
0	0	O
		
The	DT	O
usual	JJ	O
adult	NN	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablespoonful	NN	UNIT
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
0	0	O
		
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ZYTIGA	NNP	O
is	VBZ	O
1000	CD	DOS
mg	NN	UNIT
(	(	O
four	CD	DOS
250	CD	O
mg	NNS	O
tablets	NNS	UNIT
)	)	O
administered	VBD	O
orally	RB	O
once	RB	O
daily	JJ	O
in	IN	O
combination	NN	O
with	IN	O
prednisone	NN	O
5	CD	O
mg	NN	O
administered	VBN	O
orally	RB	O
twice	JJ	O
daily	RB	O
0	0	O
